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Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and
accounts for 30 - 35% of all cancers in children. Significant improvement in the treatment
of pediatric ALL has been achieved in recent years. Only 50 years ago, the disease was
uniformly fatal with an Overall Survival (OS) rate < 5%. Modern-day, multi-drug
chemotherapy is associated with an overall survival rate over 80%. Standard-risk ALL
comprises the majority of ALL with an overall survival approaching 90%. Despite this
success, children who relapse from this disease accounts for the majority of cancerrelated deaths in children. The backbone of treatment protocols have incorporated
somatic but not host genetic features in the treatment regimens. The current study
examined 12 genetic polymorphisms affecting the pharmacodynamics of antileukemic
drugs in an attempt to identify biologic markers related to the risk of disease relapse.
In the current research program, 125 standard-risk ALL patients who were treated
at The Children’s Hospital were enrolled in a retrospective study. Statistical analysis was
performed to evaluate the association between genetic polymorphisms and risk of disease
relapse in this study cohort. The GSTM1 null genotype was associated with a decreased
risk of disease relapse (HR = 0.394, 95% CI = 0.127 - 1.224, P = 0.107). A combination
analysis of the GSTM1 and GSTT1 genotypes revealed a stronger association between the

ii

both the GSTM1 and GSTT1 normal genotype and an increased risk of leukemia relapse
(HR = 2.73, 95% CI = 0.9 – 7.9, P = 0.063), compared with patients having either the
GSTM1 or GSTT1 null genotype. A “drug exposure” model was used in this study. The
risk of relapse in individual with a low or intermediate “drug exposure” genotype
increased 2.4-fold (HR = 2.39, 95% CI = 0.8 – 6.9, P = 0.107) compared with the high
“drug exposure” genotype. No significant associations with relapse were observed for the
CYP1A1, CYP2B6, CYP3A4, CYP3A5, MTHFR C667T, MTHFR A1298G, or TYMS
polymorphisms. The findings from this single institution study suggest that
polymorphisms within genes of the GST superfamily may influence the treatment
outcome in standard-risk ALL. They also point to the need of prospective, large multiinstitutional studies to validate these findings prior to clinical implementation.
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Chapter 1
Introduction
The successful treatment of childhood acute lymphoblastic leukemia represents
one of the great medical accomplishments of the 20th century. Only five decades ago this
disease was uniformly fatal. Since the introduction of multi-drug chemotherapy, the cure
rate has risen to over 80%. In fact, the most recent results from the patients with ALL
enrolled in Children’s Oncology Group (COG) protocols showed an improvement in the
5-year overall survival rate from 83.6% to 90.3% over the last decade (Friedrich 2009).
This success reflects the use of risk-directed therapy in which clinical variables related to
the patient (e.g., age and leukocyte count at initial diagnosis) and biological variables
specific to the leukemic cell population (e.g., DNA ploidy, ETV6/RUNX1 chromosomal
translocation and Philadelphia chromosome) were used to stratify treatment (Sather 1986,
Crist 1986, Seeger 1998, Heerema 2000). Unfortunately, ALL continues to be the leading
cause of cancer-associated death in children despite improved treatment regimens.
Moreover, the cure rate in patients who experience disease relapse has not improved over
the past decade. Due to drug toxicity, simple increases in chemotherapeutic drug doses to
decrease the relapse rate do not represent a viable solution. As seen in the most recent
1

COG protocols, the therapeutic limits of these toxic drugs have already been maximized
(Landier 2008). Additionally, the long-term consequences of relapsed ALL include
secondary malignancies, growth retardation, and cognitive impairments. More than twothirds of ALL patients reported at least one adverse late effect, and half of those reported
an event that was severe or life-threatening.
In order to eradicate the leukemic cells, cytotoxic drugs typically have to be used
at maximum dose intensity. These drugs are then administered as frequently as possible
to discourage tumor regrowth. One of the greatest challenges of leukemia treatment,
therefore, is to adjust the drug dose to achieve the desired therapeutic outcome while
limiting toxicity. Drug dosages have been administered based on the patient’s body
surface area or weight for decades. This practice, however, is not based on solid research
studies and has not taken into consideration the patient’s renal and hepatic functions,
bone marrow reserve, or concurrent medical conditions (Sawyer 2001). Great efforts
have been focused on dosage adjustment, based on renal function, to attain a desired drug
concentration in plasma or area under the concentration-time curve (AUC) – an important
factor in determining the tissue exposure to the drug. The successes of this approach were
exemplified by methotrexate (MTX) dose adjustment for pediatric ALL therapy. Relling
(1999a) demonstrated that the therapeutic outcome was related to achieving a target MTX
plasma concentration during high-dose therapy. Dose adjustment based on monitoring of
steady-state MTX levels improved treatment outcome. On the other hand, genes encoding
drug-metabolizing enzymes can influence the efficacy and toxicity of chemotherapy
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(Evans 1999). Despite efforts to anticipate drug complications, however,
chemotherapeutic agents have variable pharmacokinetics and toxicity in individual
patients. The causes of this variability are not always clear but are thought to be related to
interindividual differences in drug metabolism and drug interactions.
Treatment outcome is dependent not only on chemotherapy used, but also on the
underlying biology of the host. Thus, numerous important biologic and therapeutic
questions remain to be answered in order to achieve the goal of curing every child with
ALL. With the completion of Human Genome Project, comprehensive studies of genetic
polymorphisms in drug-metabolizing enzyme genes and drug-target genes have become
possible. This information may make it possible to better customize drug dosage levels
and drug combinations for individual patients. Insights into the role of host genetic
variations will likely further improve the treatment outcome by integrating
pharmacodynamic and pharmacogenomic studies to individualizing treatment regimen
for children with acute lymphoblastic leukemia.

1.1.

Hypotheses and specific aims

1.1.1. Specific Aim 1
To determine the genotypes of CYP1A1, CYP2B6, CYP3A4, CYP3A5, GSTT1,
GSTP1, TYMS, and MTHFR genes from patient DNA samples.
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1.1.2. Specific Aim 2
To identify the genetic polymorphisms of those genes that influence the treatment
outcome in standard-risk ALL patients.
Hypothesis 1: Variations in the drug-metabolism genes, individually or in combination,
will be associated with the treatment outcome in standard-risk ALL patients.
Hypothesis 2: Variations in the drug-target genes, individually or in combination, will be
associated with the treatment outcome in standard-risk ALL patients.

1.1.3. Specific Aim 3:
To identify the possible association between the host genetic variation and
ETV6/RUNX1 fusion transcript status in standard-risk ALL patients.
Hypothesis: Host genetic variations (i.e., drug-metabolism and drug-target gene
polymorphisms), individually or in combination, will be associated with ETV6/RUNX1
fusion transcript status.
These specific aims, taken together, represent a first step toward understanding the
relationship between host genetic variations and treatment outcome in this clinically
defined “homogeneous” group of patients.

4

1.2.

Significance
There is no doubt that host variation in the genes that encode drug-metabolizing

enzymes and drug targets has the potential to alter drug serum concentration levels and
molecular target engagement. The ultimate goal of pharmacogenetic studies is the
individualization of drug dosage to each patient so as to achieve the maximum treatment
efficacy while limiting toxicity. This study is significant for many reasons. First, this
study will identify host genetic features that may affect the efficacy and toxicity of antileukemic chemotherapy. Second, this study will obtain pertinent information regarding
the potential association between genetic polymorphisms (alone or in combinations) and
disease relapse in patients treated for pediatric standard-risk ALL. Third, this study may
help to further refine risk-classification for pediatric ALL patients. This study represents
a unique opportunity to provide data to further optimize treatment regimens for individual
patients regardless of their presenting characteristics.
Given the potential for genetic variation to influence patient response to drug
treatment regimens, this work is particularly important in terms of its potential for
improving the therapeutic outcome for children with lymphoblastic leukemia.
Futhermore, this will be the first study conducted using a “homogeneous” cohort.

5

1.3.

Outcome Measure(s)
The primary outcome is to identify whether or not there exists an association

between polymorphisms in the CYP1A1, CYP3A4/5, CYP2B6, GST, TYMS, and/or
MTHFR genes and with treatment outcome (i.e., relapse vs. no relapse) for standard-risk
ALL. This study should be considered preliminary in nature due to the limited number of
patients.
The secondary outcome measures are to: 1) identify the frequencies of individual
polymorphisms in the CYP1A1, CYP3A4/5, CYP2B6, GST, TYMS, and MTHFR genes in
standard-risk ALL patients who carry the ETV6/RUNX1 fusion transcript; 2) explore the
potential effects of combinations of genetic polymorphisms (or gene-gene interactions)
on the treatment outcome of standard-risk ALL.
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Chapter 2
Background

2.1.

Acute Lymphoblastic Leukemia
Leukemia or leukaemia (Greek leukos λευκός, "white"; aima αίμα, "blood")

literally means “white blood” and is a cancer of the blood or bone marrow characterized
by an abnormal increase of blood cells, usually leukocytes (white blood cells). It is part
of the group of diseases categorized as hematological neoplasms. Depend on their
progression, leukemias are usually divided into two major groups based on their clinical
behavior. These are: 1) Acute Leukemia, which progresses quickly with many immature
white cells; and 2) Chronic Leukemia, which progresses slowly with more mature white
cells (Pui 2006).
Normally, the bone marrow contains self-renewing hematopoietic stem cells
which develop into different types of mature blood cells including B lymphocytes, T
lymphocytes, natural killer cells, various types of granulocytes, red blood cells, and
platelets (Figure 2.1). ALL results from the clonal expansion of lymphoid cells arrested at
an early stage of differentiation. ALL accounts for 75% of childhood leukemia cases with
7

an incidence of 3-4 children per 100,000 individuals. Thus, between 2500 and 3000
children in the United States are diagnosed annually. ALL is the most common cancer in
children representing about 25-35% of all childhood cancers and its diagnosis peaks
between the ages of 2 and 5 years (Xie 2003). The incidence of the disease for this age
group is approximately 4-fold higher than that for infants and is close to 10-fold higher
than that for adolescents (ages 16 – 21 years) (Ries 2010). If leukemia is left untreated, it
is uniformly fatal. A long list of often conflicting epidemiologic and environmental
studies has attempted to elucidate the etiology of ALL. Two parallel infection-based
hypothesis have been postulated based on an abnormal responses to infection; a peak in
ALL incidence at 2-5 years of age; increased prevalence of the disease in the developed
countries; and the presence of some geographical case clustering.
Kinlen (2004) predicts that excess cases of childhood leukemia result from exposure to
common but low-pathologic infections after population-mixing with carriers occurs. This
hypothesis was supported by a U.S study (Wartenberg 2004) through US SEER data.
However, other studies have shown higher incidence of ALL in urban or high-density
regions (Li 1998, Hjalmars 1999, Adelman 2005). Greaves (2006) suggested a delayedinfection hypothesis based on a two-hit model involving a delayed and dysregulated
immune response to common infectious pathogens which leads to the transformation of
pre-leukemic cells into acute lymphoblastic leukemia. So far, there is little evidence to
support any role of viral transformation as a cause. Furthermore, it does not appear that
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there is a single cause for childhood ALL – for most patients, a combination of factors
appears necessary. Possible genetic causes of the disease will be discussed later.

Figure 2.1 Blood cell development. Several steps are needed for a blood stem cell to
become a red blood cell, platelet, or white blood cell.
http://www.cancer.gov/cancertopics/pdq/treatment/childALL/HealthProfessional/ last
accessed Nov. 20, 2010

There are conflicting reports of factors that pose an increased risk for ALL,
including parental occupation; maternal reproductive history; parental exposure to
pesticides; and even exposures to high levels of residential electric and magnetic fields
(Ahlbom 2000, Buffler 2005). Recurrent genetic abnormalities have also been observed
in ALL patients, including chromosomal translocations that deregulate gene expression;
chromosome copy number variations; and gene-specific mutations. The precise biological
9

and genetic mechanisms that lead to the development of ALL, however, remain
unknown. Based on phenotypic observation and experimental models, however, it likely
involves genes that control lymphoid cells differentiation, resulting in a clonal neoplastic
disorder of the hematopoietic system. Recently, studies suggest that the etiology of ALL
may be linked to a variety of genetic lesions in blood progenitor cells that are committed
to differentiation or in some cases to lesions that arise in a hematopoietic stem cell (HSC)
that has multi-lineage differentiation capacity The cellular microenvironment also
appears to have an impact on leukemic cell transformation (Armstrong 2005, Wang 2005,
Barabe 2007).

2.2.

Clinical Features
The clinical presentation of ALL is often acute, although a small percentage of

cases evolve slowly over several months (Pui 1998 and 2006). The common symptoms
include fever, fatigue, bone or joint pain and bleeding. These presenting symptoms
correlate with the uncontrolled growth of the malignant cell population invading the bone
marrow, lymphoid organs, and extramedullary (outside of the bone marrow) sites.
Anemia, neutropenia, thrombocytopenia, lymphadenopathy, splenomegaly, and
hepatosplenomegaly are common clinical features. Bone pain is common among younger
children with ALL, whose first symptom is often the onset of a limp or a refusal to walk.
These result from the infiltration of periosrteum by leukemic cells, bone infarction, or
expansion of the marrow cavity. Findings at initial physical examination are usually
10

unremarkable. Asymptomatic lymphadenopathy and hepatosplenomegaly occur in more
than half of patients. The most common affected extramedullary site is the central
nervous system (CNS). Although CNS involvement at diagnosis is relatively uncommon,
when symptoms do occur, the clinical features can include headache, nausea and
vomiting, lethargy, and irritability. The common clinical features of ALL are presented
in Table 2.1. Other symptoms include:
•

Fatigue

•

Paleness resulting from anemia caused by insufficient numbers of red blood
cells.

•

Recurrent minor infections due to insufficient numbers of healthy mature white
blood cells to fight off infection.

•

Fever without a known cause

•

Bruising, poor healing of minor cuts, uncontrolled bleeding due to insufficient
numbers of platelets (thrombocytopenia).

11

Table. 2.1 Clinical and Laboratory Features in Childhood ALL
Features

% of Patients*

Clinical Presentations
Fever
Bleeding
Bone and joint pain
Splenomegaly
Hepatomegaly
Lymphadenopathy
Abdominal pain

55
45
30
60
70
50
10

Laboratory Features
WBC count (X 103/μl)
< 10
10 - 49
>50
Hemoglobin (g/dL)
<7
7 - 11
>11
Platelet count ( X 103/μl)
< 20
20 - 99
>100
*The percentages are approximations

50
30
20
43
45
12
30
50
20

12

2.3.

Diagnosis
Several procedures can be employed to help confirm the diagnosis of ALL. These

include a complete morphologic, immunologic, and genetic examination of the leukemic
cells. This is essential to establish the diagnosis of acute lymphoblastic leukemia. The
cellular hallmark of ALL, is the presence of lymphoblasts, a relatively undifferentiated
cell with diffusely distributed nuclear chromatin, one or more nucleoli, and a basophillic
cytoplasm. Accurate diagnosis and classification are the foundation for the successful
treatment and biologic study of childhood acute leukemia. Modern classification of
leukemia is based on the incorporation of morphologic findings, immunophenotype, and
genetic abnormalies, in an attempt to define homogeneous disease subtypes that are
clinically and biologically relevant.

2.3.1. Laboratory:
Clinical laboratory findings are usually unremarkable for ALL. The most
common laboratory findings in ALL include anemia, thrombocytopenia, neutropenia, and
leukocytosis. Other laboratory abnormalities include increased serum levels of uric acid,
potassium, phosphorus, calcium, and lactate dehydrogenase (LDH). The degree of
abnormality reflects the leukemic cell burden and cell lysis. Coagulation studies
including prothrombin time (PT), activated partial thromboplastin time (aPTT),
fibrinogen level, and D-dimer level are used to assess the degree of disseminated
intravascular coagulation (Pui 2006).

13

2.3.2

Pathology:

2.3.2.1. Morphology
The morphologic diagnosis of leukemia consists of two broad steps. First, is
establishing a general diagnosis of leukemia and second is classifying the leukemic
process. For most patients with ALL, examination of the peripheral blood smear is
normally sufficient to reveal leukemic lymphoblasts. Definitive diagnosis, however,
usually requires examination of the bone marrow. According to the WHO, at least 25%
blast cells are required to render a final diagnosis of acute leukemia. More than three
fourths of patients, however, have more than 50% lymphoblasts in the bone marrow at
initial presentation.
The lymphoblasts in ALL are relatively uniform in appearance with round to oval
to indented nuclei under a light microscope. The classic morphologic characteristics of
ALL were established by the 1976 French-American-British (FAB) system, based on the
microscopic features of the leukemia cells using Wright-Giemsa-stained smears. The
FAB classification system groups ALL into three morphologic sub-groups designated L1,
L2, and L3 (Bennett 1981). In the most common subtype L1, the lymphoblasts appear
small in size, with scant cytoplasm, homogeneous nuclear chromatin and indistinct or
absent nucleoli. The less common L2 sub-type presents with large cell size, more
heterogeneous nuclear chromatin, irregular/clefting nuclear shape and prominent
nucleoli. In practice, the majority of ALLs show a morphologic spectrum between the L1
14

and L2 subtypes, making the distinction between these categories somewhat arbitrary.
The L3 sub-type is rarely seen. It consists of large blasts, regular nuclear features, with an
abundant deeply basophillic cytoplasm, finely stippled chromatin, and often prominent
nucleoli. Subsequent studies involving the immunophenotype and molecular biology of
Burkitt lymphoma, revealed the L3 subtype was the leukemic phase of non-Hodgkin’s
lymphoma with a mature B-cell immunophenotype (Hecht 2000). Up to 10% of
lymphoblast cells may depart from the characteristics of each morphology sub-type. The
FAB system lacks independent prognostic significance and thus is seldom used in current
medical practice.

Figure 2.2 Morphological representation of lymphoblasts. L1, left; L2, middle; L3, right.
Source: Dept. of Pathology, The Children’s Hospital, Aurora, CO.

2.3.2.2. Immunophenotype
The diagnosis and treatment of ALL are depended on the recognition of a
leukemic population, its lineage, and sometime its stage of maturation.
Immunophenotypic studies are an essential part of the diagnostic workup of ALL; the
15

results complement morphologic studies by establishing the leukemic cell lineage,
determining the precise stage of differentiation, and often clonality. Unlike morphologic
features, immunophenotyping divides acute leukemia into two broad, but clinically and
biologically meaningful, categories: B-cell ALL (B-ALL) and T-cell ALL (T-ALL).
Several hundred monoclonal antibodies have now been assigned to over 300
cluster differentiation (CD) groupings by the International Workshops on Leukocyte
Differentiation Antigens (Manson 2002). A panel of antibodies is used to establish the
diagnosis of ALL by flow cytometry. This process includes include at least one marker
that is highly lineage specific. For example, CD19 marks the B-lineage; CD7 marks the
T-lineage; and CD33 marks myeloid lineage cells. For the B-lineage, the panel often also
includes PAX-5 (B-cell specific activator protein), CD20, CD22, and CD79a. A large
percentage of B-ALL cases also show expression of CD10 (common acute lymphoblastic
leukemia antigen). Other markers should be included for a diagnosis of pre-B cell ALL.
These include CD34 and terminal deoxynucleotidyl transferase (TdT). The pre-B-cell
group accounts for 80% of ALL cases and is subdivided on the basis of cytoplasmic
immunoglobulin (Ig) expression into early pre-B-ALL (which lacks the Ig expression),
pre-B-ALL (with expression of cytoplasmic µ chains, but without Ig light chains), and
transitional pre-B-ALL (with cytoplasmic and weak surface expression of µ chains,
without Ig light chain expression) (Swerdlow 2008, Li 2003).
T-ALL is characterized by the expression of the T-lineage-associated antigens
CD2, CD3, CD4, CD5, CD7, CD8 as well as CD10, CD34, HLA-DR, and TdT
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(Swerdlow, 2008). The current study is focused on B cell ALL, so T-ALL will not be
discussed further.

2.4.

Genetic Features
Despite relatively homogeneous morphologic and immunophenotypic features,

ALL displays significant heterogeneity at the genetic level. The genetic characteristics
define disease subsets with distinct biologic behavior and prognostic implications. They
are used in the risk stratification for most modern treatment protocols. Molecular
techniques have contributed greatly to our understanding of the pathogenesis and
prognosis of ALL through the discovery of various common genetic alterations that occur
in leukemic cells. The general underlying mechanisms of ALL are similar. They consist
of aberrant proto-oncogene expression; chromosomal translocations that generate fusion
transcripts encoding active kinases and altered transcription factors; and hyperdiploidy (≥
50 chromosomes per cell). These genetic alterations are linked to essential changes in
cellular regulation and function that support the leukemic transformation of
hematopoietic stem cells. These genetic changes enhance the cell’s capacity for self
renewal by altering the normal cell proliferation, blocking differentiation, and promoting
resistance to programmed cell death (apoptosis).

2.4.1. Chromosomal abnormalities
ALL is associated with several chromosomal abnormalities with distinct biologic
features that are critical for modern risk stratification. These abnormalities occur in 60 –
17

80% cases of childhood ALL. The clinicopathologic and genetic features of the major
genetic abnormalities seen in ALL are summarized in Table 2.2. Hyperdiploidy occurs in
almost 30% of ALL cases with favorable prognosis. Leukemia cells with hyperdiploidy
are more susceptible to the induction of apoptosis and the accumulation of high levels of
chemotherapeutic agents or their metabolites. This may explain the favorable outcomes
typically observed in these patients. Trisomy (extra copies of certain chromosomes) is
another favorable prognostic factor observed in some ALL patients. Patients whose
leukemic cells have extra copies of chromosome 4 and 10 appear have a particularly
favorable outcome among hyperdiploid ALL patients. The presence of trisomies 4 and 10
has been incorporated into current treatment protocols. Approximately 1% of childhood
ALL cases have less than 45 chromosomes, a condition termed hypodiploidy. These
patients are at high risk for treatment failure. A significant, progressively worse outcome
is seen for ALL patients with a decreasing numbers of chromosome. Patients with 24 –
46 chromosomes have the worst outcome.

2.4.2. Chromosomal translocations
Recurring chromosomal translocations can be detected in approximately 35 –
40% of childhood ALL patients. In some cases, this has prognostic significance (Figure
2.3). Currently, there is little evidence as to whether translocations are a product of errors
in the DNA processing or are caused by external factors such as chemicals or viruses.
However, most translocations are not sufficient to cause disease since they are more

18

common (perhaps by up to 100-fold) in the general population than their associated
leukemias (Eguchi-Ishimae 2001, Mori 2002).
ETV6/RUNX1 [molecular counter part of t(12;21)] is most commonly observed
genetic lesion in childhood B-ALL (22 – 25% of cases) but it is only rarely seen in T-cell
ALL. This genetic lesion is thought to arise in utero in a B precursor cell during fetal
hematopoiesis to generate a pre-leukemia clone. It has been suggested, therefore, that
this translocation is an initiating event in B-ALL (Greaves 2006). Patients with
ETV6/RUNX1 are generally diagnosed with B-ALL between the ages of 2 – 9 and have
excellent treatment outcome even in the case of relapsed patients. The ETV6/RUNX1
fusion transcript probably inhibits the transcription of the normal RUNX1 gene involved
in the proliferation and differentiation of hematopoietic cells. This phenomenon has been
clearly observed in clinical trials featuring intensive chemotherapy with asparaginase
(Elspar®, Merck & CO., Inc). Interestingly, leukemic cells that express ETV6/RUNX1 are
highly sensitive to asparaginase in vitro.
BCR-ABL1 fusion transcripts [known as a Philadelphia chromosome, t(9;22)] are
formed as a head-to-tail fusion of the breakpoint cluster region (BCR) gene on
chromosome 22 with the Abelson gene (ABL1) on chromosome 9. BCR-ABL1 encodes
two distinct BCR-ABL1 oncoproteins, termed p210 and p190, that arise from two
different splice sites in the BCR gene (Heisterkamp 1985). In chronic myeloid leukemia
(CML), the BCR-ABL1 fusion transcript (p210) originates in HSC, whereas the p190
fusion in pediatric ALL appears to arise in a lymphoid lineage precursor. It (p190) is
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observed in approximately 3% of childhood ALL cases and it confers an unfavorable
prognosis, especially when associated with a high White Blood Cell (WBC) count at the
time of diagnosis. Philadelphia-positive ALL has higher frequency in older patients,
shows poor response to prednisone, and is associated with a higher level of residual
disease after induction chemotherapy.

E2A-PBX1 fusion transcript [molecular counter part of t(1;19)] occurs in 3 – 6%
of childhood ALL cases and exits as either a balanced or an unbalanced translocation.
This rearrangement generates a fusion transcript that encodes a chimeric transcription
factor from the amino-transactivation domain of E2A and the DNA-binding domain of
PBX1 (Kamps 1990). E2A-PBX1 may contribute to leukemogenesis by binding and
sequestering normal partners of the PBX protein, such as HOX proteins – thereby leading
to uncontrolled cell-cycle progression (Aspland 2001). This is primarily observed in the
pre-B ALL (i.e., cytoplasmic Ig positive). Some studies suggested that patients with a
balanced t(1;19) translacation may do worse than patients with an unbalanced
translocation, but this remains a point of debate due to inconsistencies between studies on
the subject.
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Figure 2.3 Distribution of chromosomal abnormalities in ALL.
Data were modified from Pui and Downing to exclude the T-cell genotypes (Pui and
Downing, 2004)
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Table 2.2 Cytogenetic subtypes of pre-B ALL and their clinical/pathological features
Cytogenetic
Subgroup

Frequency
(%)

Cytogenetic
Abnormality

Immunophenotypic Features

Hyperdiploid
27-29
ALL

51 -65
chromosomes

NA

ALL with
t(12;21)

t(12;21)(p13;q22)

Early pre-B
ALL
My+
Pre-B ALL
CD9++
CD20CD34/dim+

22-25

ALL with
t(1;19)

3-6

t(1;19)(q23:p13)

Philadelphia
+ ALL

2-3

t(9;22)(q34;q11.2) NA

ALL with
t(v;11q23)

2-3

t(4;11)(q21;q23)
t(9;11)(p13;q23)

Early pre-B
ALL
CD10CD15+
CD65+

Hypodiploid
ALL

5-6

< 46
chromosomes

NA

Pharmacologic
Features

Prognostic
Category

Higher
sensitivity
Favorable
to MTX, 6MP
Higher
sensitivity
Favorable
to
asparaginase

NA

Unfavorable

NA

Unfavorable
High-risk

Higher
sensitivity
to
cytarabine

Unfavorable
High-risk

NA

Unfavorable
High-risk

MTX, methotrexate; 6-MP, 6-mercaptopurine; My, myeloid antigens; Pre-B, precursor B; NA, not applicable.
Adapted from Mihaela, O. “Acute Lymphoblastic Leukemia” Hematol Oncol Clin N Am 23 (2009):655-74.
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2.5.

Prognostic Groups
The National Cancer Institute (NCI) classifies childhood ALL patients into

different treatment regimen groups. Patients between 1- 10 years old who have a white
blood cell count of less than 50,000/μl at diagnosis are classified as standard-risk ALL.
The remaining patients are classified as high-risk ALL. The very high-risk group is
defined by the presence of t(9;22) or hypodiploidy.
The prognosis of childhood ALL has improved dramatically over last five
decades as a result of adapting therapy to the level of risk of disease relapse and continual
reconfiguration/optimization of existing chemotherapeutic drugs.

2.6.

Treatment
Leukemia is a systemic disease the treatment for which is primarily based on the

use of chemotherapy. The backbone of contemporary multi-drug chemotherapeutic
regimens consists of three treatment stages: induction, consolidation/intensification, and
maintenance (Figure 2.4). Successful treatment of children with ALL requires the control
of systemic disease as well as treatment of extramedullary disease – particularly in the
central nervous system (CNS) because systemically administered anti-leukemic drugs do
not cross the blood-brain barrier. CNS prophylaxis therapy, therefore, is generally
administrated during each treatment stage. The general aim of therapy in ALL is to cure
the patient of the disease which includes: 1) to induce a clinical and hematologic
remission; 2) to maintain remission by systemic chemotherapy and prophylactic CNS
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The treatment protocol was obtained from the Center for Cancer and Blood Disorders, The
Children’s Hospital.

Figure 2.4 CCG-1952 Standard-risk ALL Therapy. VCR: Vincristine; PDN: Prednisone; ASP:
Asparaginase; MTX: Methotrexate; CPM: Cyclophosphamide; 6-MP: 6-Mercaptopurine; ARA-C:
Cytarabine; IT-MTX: Intrachecal Methotrexate; IT-ARA-C: Intrachecal Cytarabine.

therapy, and 3) to treat any complications arising from the therapy or the disease. The
following section will discuss these approaches in greater detail.

2.6.1. Induction
The goal in this treatment stage is to eradicate the signs and symptoms of the
disease and to restore normal hematopoiesis. Success of this stage is marked by “clinical
remission” (CR). A patient in CR must have no morphologic evidence of leukemia (i.e.,
<5% lymphoblasts) and a normal complete blood cell count (CBC). CR status also
includes the absence of detectable CNS or extramedullary disease as evaluated by
microscopic examination of the bone marrow and cerebrospinal fluid (CSF). The
treatment regimen consists of a 3-drug (vincristine, steroids and asparaginase) or a more
intense 4-drug (i.e., adding anthracycline to the previous mix) treatment combination. For
patients who are at standard-risk of treatment failure, the more intense 4-drug induction
therapy appears not to be necessary. In general, more than 95% of ALL patients will
achieve a complete remission within the first 4 weeks after diagnosis. Day-28 bone
marrow is evaluated morphologically for CR and its minimal residual disease (MRD)
status. Those cases that show a very slow response to induction therapy typically receive
an additional 2 weeks of treatment after which, a bone marrow sample is evaluated.
Patients with induction failure (< 3%) and a high-risk status receive an additional 4-drug
therapy. The early institution of adequate CNS prophylaxis therapy is critical for
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eliminating CNS disease and preventing CNS relapse in patients without clinical CNS
involvement at diagnosis. Intrathecal chemotherapy may be the most effective form of
presymptomatic CNS therapy. Alternately, methotrexate alone, methotrexate in
combination with cytarabine plus hydrocortisone and/or cranial radiation may be used.
This regimen usually started at the beginning of induction, intensified during the
consolidation stage, and often continued throughout the maintenance stage. The CNS
relapse rate is less than 5% for the standard-risk ALL patients treated with this regimen.

2.6.2

Consolidation
Early studies demonstrated that disease remission alone is insufficient to cure

ALL. A significant amount of additional therapy is required to eradicate all malignant
lymphoblasts – thus reducing the risk of relapse. Although the importance of this
treatment phase is very clear, there is little consensus on the best regimens and duration
of treatment. The most commonly used strategies include high-dose methotrexate plus
mercaptopurine and reinduction with the same chemotherapeutic agents that had been
administered initially. The consolidation stage also includes systemic chemotherapy
treatment in conjunction with additional CNS sanctuary therapy. The Children’s Hospital
of Denver belongs to the COG, and thus, its regimen consists of a combination of 6mercaptopurine, vincristine, corticosteroids, and methotrexate with intrathecal therapy.
This stage usually lasts 3 months. Afterwards, a delayed intensification phase (3 months)
with asparaginase, cyclophosphamide, doxorubicin, and cytarabine is initiated. This
approach has significantly improved the outcome in standard-risk ALL cases.
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2.6.3.

Maintenance
For reasons that are still poorly understood, patients with ALL require

continuation treatment to effectively prevent relapse of the disease. Although
approximately two-thirds of ALL patients can be treated successfully with only 12
months of therapy, prospectively indentifying those patients with any certainty is
impossible (Toyoda 2000). Therefore, all patients receive additional therapy. The last
stage (maintenance) of treatment for childhood ALL includes low dose daily oral
mercaptopurine and weekly intravenous methotrexate administration. Maintenance
therapy is the longest stage for ALL patients. It generally continues for 2- 3 years from
the point of complete remission. In some protocols, additional pulses of vincristine and
corticosteroids may be added. A COG randomized trial demonstrated an improved
outcome for patients receiving vincristine/prednisone pulses. A meta-analysis of data
from multiple clinical trials showed increased event-free survival as well. The CCG-1952
protocol illustrates the common approach used to treat standard-risk ALL (Table 2.3).

2.7.

Clinical Trial Results
The clinical trials from most large cooperative groups between 1980 and 1990

showed very similar results (Table 2.4). An improvement in ALL treatment outcome was
obtained using very different treatment strategies, however, all of these shared a common
approach toward treatment intensification.
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Data from the Berlin-Frankfurt-Münster (BFM) group showed an improvement
from a 66% successful rate in treating ALL patients in 1981 (ALL-BFM 81) to a 76%
success rate in 1990 (ALL-BFM 90). These results demonstrated that delayed
intensification is a crucial component of treatment. Other information obtained from
BFM-90 study was that certain time-points during the post-induction minimal residual
disease evaluation helped to identify more precisely those patients at high risk for relapse.
The COG reported marked improvement during their two successive trials (1983-1988
and 1989-1995). Overall 10 year event-free survival (EFS) was 62% for the 1983-1988
study and 72% for the 1989-1995 study. Delayed intensification was deemed to be the
most crucial factor responsible for the improved therapeutic outcome. The St. Jude
Children’s Research Hospital (SJCRH) reported that in their recent trial (Total XIII),
early intensification of intrathecal therapy yielded a 5-year EFS of 79% (Pui 2004).
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Table 2.3 Treatment details for CCG 1952 (Standard-risk ALL)

Source: Matloub Y, et al. (2006) Blood, Vol. 108: 1165-73.
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Table 2.4 Results of Selected Clinical Trials in Children with ALL
Study Group

Duration

No. of Patients

5-Yr EFS (%)

ALL-BFM 90

1990-1995

2178

78±1.0

CCG-1800

1989-1995

5121

75±1.0

SJCRH XIII

1991-1998

412

79.4±2.3

NOPHO ALL-92

1992-1998

1143

77.6±1.4

COALL-92

1992-1997

538

76.9±1.9

Source: Pui and Downing (2004)

Treatment outcome for childhood acute lymphoblastic leukemia has improved
dramatically over the past three decades. The 5-year survival rate increased from 53% in
1974-76 to 80% in 1992-99. Figure 2.5 illustrates survival rates of successive CCG
protocols (Hunger, 2010). These successes are in large part the result of new
combinations and schedules of chemotherapy using establish agents rather than the result
of new drug development. Despite this success, 25% of ALL patients ultimately relapse
and at least 15% of patients die. Relapsed leukemia, on its own, represents the fourth
most common malignancy in children. These numbers are greater than for children
diagnosed with other pediatric malignancies including osteosarcoma, Ewing sarcoma and
retinoblastoma. Thus, the overall prognosis for relapsed patients remains unsatisfactory
despite recent improvements in treatment outcome.
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Figure 2.5 Survival curve for CCG treatment protocols
Source: Stephen Hunger, M.D. (personal communication)

ALL can reappear in the bone marrow, central nervous system, testis, and other
extramedullary “sanctuary” sites. Diagnosis is made by morphologic confirmation of
lymphoblasts at relapse sites. Medullary ALL relapse is defined as the presence of ≥ 25%
lymphoblasts in a bone marrow sample following the first complete remission. CNS
relapse is defined as the presence of mophologically distinct lymphoblasts on a CSF
cytospin with ≥ 5 blasts per microliter (µl). Testicular relapse is defined as the
histological findings of lymphoblastic infiltration in one or both testes. The
immunophenotypic features of relapsed ALL are largely similar to those seen in the
diagnostic samples. Treatment of relapsed ALL varies between the different cooperative
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groups. Typical treatment of a first relapse is often similar to the induction therapy
employed in response to the initial diagnosis of ALL, and thus, it involves a combination
of vincristine, a glucocorticoid, and asparaginase, plus an anthracycline, methotrexate, or
cytarabine in varying doses and schedules. All patients who experience a second
remission receive additional chemotherapy to maintain control of their disease.
Hematopoietic stem cell transplantation (HSCT) is often offered to all patients with early
bone marrow relapse. Fundamentally, both additional chemotherapy and hematopoietic
cell transplantation are risky approaches and neither is highly effective for curing most
ALL patients with bone marrow relapse.
A recent Children’s Cancer Group study of 9,585 children with newly diagnosed
ALL between 1988 and 2002 found that a total of 1,961 patients (20.5%) experienced a
relapse involving various sites throughout the body (i.e., bone marrow: 70.8%, CNS
21.9%, testicular 5.3%, and other extramedullary sites 3%) (Nguyen 2008). Malempati et
al. (2007) recently summarized the data from the CCG-1952 study (NCI standard-risk
ALL), which revealed an overall 6-year estimated EFS of 81.6%. Of the 2,174 patients
enrolled in this study, 347 relapsed after achieving complete remission following
induction therapy. Among the relapsed patients, 149 (42.9%) had isolated bone marrow
relapse and 68 (19.6%) had a relapse involving both bone marrow and extramedullary
tissues. Isolated extramedullary relapse was seen in 130 (37.5%) patients. A subsequent
relapse event (i.e., after the first relapse) was seen in 151 patients during the 2.4 year
follow-up period. Among the patients with a second event, 21 (13.9%) died from either
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toxicity of the chemotherapeutic agents during reinduction therapy or reinduction failure
leading to a major bone marrow or extramedullary relapse. A total of 41 patients (27.2%)
died in second remission with 28 succumbing to complications from HSCT, 12 from
chemotherapeutic agent toxicity and 1 from disease unrelated to leukemia. So far, the
only factors predictive of survival after relapse are the site of relapse and the duration of
the first complete remission (CR1). Risk-stratification strategies at initial diagnosis do not
appear to be useful for predicting the outcome of this group of relapsed patients. There
was no difference in EFS between the HSCT and chemotherapy treated patients for any
relapse site or CR1 duration (Figure 2.6, Malempati 2007). Management of this group of
patients has proved extremely challenging and the long-term survival rates (i.e., 25-35%)
for relapsed ALL patients continues to be very poor (Sadowitz 1993, Buchana 2000,
Leahey 2000, Chessells 2003). Drug resistance in this heavily pretreated population may
contribute to this poor response rate.

Despite substantial second remission rates (>90% in some studies) and wide
availability of hematopoietic stem cell transplantation, most children with relapse die.
The recent COG protocols, therefore, have maximized the therapeutic limits and
increased dose intensity in primary therapy for newly diagnosed patients with ALL.
Increasing the dose of chemotherapeutic agents does not decrease the relapse rate. Some
patients pay a significant price with high rates of acute and chronic toxicities. More than
two-thirds of “cured” patients report at least one late effect, and half of them experienced
a condition that is severe to life threatening (Landier 2008). While the early data from
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Figure 2.6 Comparison of second event-free survival (EFS2) after stem-cell
transplantation and chemotherapy for bone marrow relapse. Kaplan-Meier estimate of
with transplant vs. chemotherapy is shown. Adapted from (Malempati 2007).
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studies of these newer protocols are encouraging, the cure rate among relapsed patients
has remained dismal (Friedrich 2009). This underscores the importance of optimal
primary therapy.
More worrisome, however, is that the plateau in survival rates over the last 10
years suggests that the limits of current treatment strategies may have been reached.
Moreover, the current risk-stratification model cannot identify approximately half of the
non-responding patients, and it fails to predict the individual patient who is at greatest
risk to experience severe toxicity at drug doses that would be well tolerated by most
patients (Donadieu 1998). The low predictive value of the conventional prognostic
indicators (e.g., age, WBC, and karyotype) underscores the need to develop a better risk
stratification strategy. Further improvement in treatment outcome and a reduction in drug
toxicity will require the identification and application of new prognostic factors and
treatment strategies. Ideally, these can used to optimize the treatment of patients as
individuals. An in-depth understanding of the mechanisms of leukemia and host biology
may make it possible to further refine risk stratification; thereby, resulting in the more
efficient identification of prognostic subgroups of patients as well as appropriate
therapeutic targets.
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Chapter 3

Pharmacogenetics of Acute Lymphoblastic Leukemia
Single nucleotide polymorphisms (SNPs) are the most frequent genetic variations.
They constitute approximately 90% of all human genome variation; they occur every 100
to 300 bp (Lander 2001); and, by definition, all SNPs are present in at least 1% of
population.
This genetic variation may play a very important role in the effectiveness and
outcome of anticancer therapies. The chemotherapeutic drugs used to treat pediatric ALL
have a narrow therapeutic range. Accordingly, they are associated with significant
mortality in addition to relapse due to drug toxicity and morbidity. They are also
associated with drug-induced second tumors. Drug-induced adverse events can be doselimiting factors in many cases, and this affects treatment outcome. Studies have shown
that adjusting dosage based on drug clearance improved ALL outcomes (Evans 1997 and
1998). Therefore, genetic variations in drug-metabolizing enzymes impact the balance
between drug efficacy and drug toxicity – which, in turn, is likely to have an important
impact on the treatment outcome in ALL.
36

Most research to date has been focused on the contributions of acquired genetic
abnormalities in leukemia blasts to the long-term outcome of the disease. Much less
attention has been given to the role of host genetic variation in determining outcome of
ALL therapy. Some insight into the molecular and cellular biology of chemotherapy
responders vs. non-responders, therefore, may be informative. The ultimate question
might be: Why do some patients fail to respond positively to therapy even though they
have the same prognostic features as those that do respond well? Genetic polymorphisms
in the genes that encode drug metabolizing enzymes and drug targets have been shown to
influence patient response to drugs including chemotherapeutic agents. The case of
Thiopurine s-methyltransferase (TPMT) exemplifies the value of this type of
pharmacogenetic research. Studied for over 25 years and increasingly utilized at beside,
TPMT is a drug-metabolizing enzyme that catalyses the S-methylation of cytotoxic and
immunosupressant thiopurines such as 6-mercaptopurine (6-MP) to yield thioinosine
monophosphate. This metabolite is then further metabolized by series of enzymes to yield
mono, di, and triphosphates of 6-thioguanosine. These metabolites, termed 6-thioguanine
nucleotides (TGNs), interfere with normal DNA and RNA synthesis which ultimately
results in cell cycle arrest and apoptosis (Weinshilboum 1983, Lennard 1992, Relling
1999). Two major thiopurine metabolic pathways exist, oxidation catalysed by xanthine
oxidase (XO) and methylation catalysed by TPMT (Figure 3.1) (Weinshilboum 2001 and
2003, Krynetski 2003). The TPMT pathway is the main mechanism of thiopurine
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metabolism in hematopoietic tissue because xanthine oxidase is not expressed in the
hematopoietic cells (Lennard 1987).
Large inter-individual differences in TPMT enzyme activity were described over
30 years ago (Weinshilboum 1980). Subsequently, the genetic polymorphisms in the
TPMT gene responsible for this phenotypic variation have been identified and
characterized (Krynetski 1995, McLeod 2000). More than 21 different TPMT SNPs have
been identified which may be associated with decreased levels of TPMT enzyme activity
and/or thiopurine-induced toxicity (Salavaggione 2005). Of those, three SNPs termed *2,
*3A and *3C account for more than 95% of the variability in TPMT enzyme activity
(McLeod 2000, Wang 2003) (Figure 3.2). Approximately 90% of the population is
homozygous for the wild-type alleles (TPMT*1) and are thus are characterized as having
“normal” enzyme activity. Approximately, 5-10% of the population are heterozygous for
TPMT and are characterized by an intermediate level of enzyme activity. Finally, 1 in
300 individuals carry two mutated alleles and are, therefore, severely TPMT-deficient
(Weinshilboum 2000, Klemetsdal 1992, Yates 1997) (Figure 3.3). The most dramatic
effect is seen in individuals with the TPMT*3A and *3B mutations which are associated
with a virtual absence of TPMT enzyme activity. TPMT-deficient patients accumulate
excessive amounts of the active TGNs within their leukocytes following administration
of 6-MP and azathiopurine. This results in severe and potentially life-threatening
hematopoietic toxicity (Evans 1991 and 2001, Relling 1999). These patients require up to
a 90% reduction in the conventional drug dosage that is administered. Interestingly, this
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dosage reduction does not appear to compromise the treatment outcome (Figure 3.4)
(Evans 1991, Relling 2006). Conversely, if TPMT-deficient patients are continually
administered the conventional dosage, they develop severe hematopoietic toxicity which
then necessitates the discontinuation of other chemotherapeutic drugs until their absolute
neutrophil count recovers. Thus, this adverse drug reaction can compromises the overall
therapeutic efficacy of the treatment protocol. TPMT deficiencies have also been linked
to an increased risk of treatment-related acute myeloid leukemia and irradiation-induced
brain tumors (Relling 1998 and1999b). To date, TPMT remains one of the few examples
of pharmacogenetic research that has been successfully translated from bench to the
bedside.
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Figure 3.1 Thiopurine Metabolism. This figure shows a simplified schematic
representation of the metabolic pathway for thiopurine drugs. The metabolic activation
occurs as series reactions catalysed by hypoxanthine guanine phosphoriboxyltransferase
(HPRT), inosine monophosphate dehydrogenase, and Guanine monphosphate synthetase.
The figure was adapted from Krynetski (2003).
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Figure 3.2 TPMT alleles. Boxes depict exons in the TPMT gene. Grey boxes are
untranslated regions, green boxes represent open reading frames, and red boxes represent
exons that contain mutations. This figure is adapted from Wang (2003).
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Figure 3.3 Frequency distribution of level of Red Blood Cell (RBC) TPMT activity
in blood samples. The genotypes are indicated as v/v (homozygous mutant), Wt/v
(heterozygous), and Wt/Wt (homozygous wild-type). This figure was modified from
Wang (2003).
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Figure 3.4 Effects of TPMT polymorphisms on the pharmacogenetics of
mercaptopurine toxicity. a) MP given at conventional dosage. TPMT-deficient patients
(v/v) show a tenfold higher systemic exposure to active thioguanine nucleotides (TGN)
than do wild-type patients (wt/wt). Heterozygous patients (wt/v) show twofold higher
TGN concentrations. The patients with higher concentrations of TGN exposure exhibit a
significantly higher frequency of haematopoietic toxicity. b) When genotype-specific
adjusted dosages are given (i.e., individualized therapy), similar cellular TGN
concentrations are achieved in all patients. All three TPMT drug metabolism phenotypes
can be treated without acute toxicity. This figure was adapted from (Cheok 2006).
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In order to assess the possible association of functional genetic variations with
ALL treatment outcome, a candidate gene approach was employed for the current
research. SNPs in genes that either mediate the disposition of chemotherapeutic agents or
their effects may modify the risk of relapse and toxicity beyond what can be predicted
from host and disease features alone (Relling 2001). The activity of drug-metabolizing
enzymes determines the bioavailability and function of many chemotherapeutic agents.
The conventional prognostic factors of age and WBC, however, have a low predictive
value for treatment response. Unfortunately, even with large clinical trials, the ability to
optimize treatment to the individual patient remains elusive. Major variables in predicting
response to leukemia therapy include hereditary and acquired variability in drug
disposition and metabolism. Although chemotherapy is the backbone of pediatric ALL
treatment, there is a paucity of pharmacogenetic studies on the major therapeutic agents.
In order to function effectively, most chemotherapeutic drugs undergo biotransformation
to form reactive and cytotoxic metabolites. This biotransformation usually involves two
stages. The first stage involves Phase I reactions which occur primarily through the
cytochrome P450 family. Phase I reactions involve the introduction of small polar groups
onto the parent drug by oxidation, reduction or hydrolysis. This step produces increased
polarity in the metabolites which may then undergo further biotransformation. In the
Phase II reactions, metabolites are conjugated with glutathione, acetate, sulfate or glycine
to produce more water soluble compounds that can be excreted in the urine (Evans 1999).
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3.1.

Drug-Metabolism Enzymes
The cytochrome P450 enzymes comprise a superfamily of 57 genes in humans –

the majority of which are involved in the metabolism of numerous drugs and xenobiotic
chemicals. Cytochrome P450 enzymes contain a heme group that can accommodate up to
6 ligands and has an absorption wavelength of 450 nm when bound to carbon-monoxide.
The naming convention specifies family, subfamily, gene, and alleles. For example,
CYP2D6*1 is allele 1 (wild type) within gene 6 of Subfamily D within Family 2 of the
CYP450 superfamily (Danielson 2002). The majority of these enzymes belongs to the
CYP1 and CYP3 families and is primarily associated with hydroxylation reactions. They
incorporate one atom of molecular oxygen into the target substrate molecule and the
remaining atom into a water molecule. This function facilitates the biotransformation of
compounds that otherwise lack functional groups suitable for conjugation. Most
chemotherapeutic drugs including cyclophosphamide, doxorubicin and vinca alkaloids
are metabolized by cytochrome P450 enzymes. Therefore, the efficacy of many of these
drugs is directly related to the levels of expression and activity of these enzymes.

3.1.1.

CYP1A1
CYP1A1 is an enzyme responsible for the aryl-hydrocarbon hydroxylase activity.

It is often associated with significant enzymatic inducibility and is highly expressed in
lymphoid cell lines (Garte 1998). This tissue specificity might correlate to an increased
risk of carcinogenesis in leukocytes. CYP1A1 is involved in the metabolic activation of
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several carcinogenic substances contained in tobacco products. Evidence exists that there
is a significant influence of CYP1A1*2 on the risk of lung cancer (Vineis 2003, Taioli
2003). Most chemotherapeutic agents involved in ALL treatment regimens are not
directly metabolized by CYP1A1. However, synthetic glucocorticoids, which are
important components of ALL treatment regimens, can induce the gene transcription
which is reflected in greater catalytic activity of CYP1A1 (Bartsch 1995). Thus, if a
patient is exposed to a carcinogenic substance (e.g., tobacco smoke), the enhanced
enzyme activity could activate, and thus increase, the toxicity of the carcinogens resulting
in an increased risk of leukemia relapse. An association was reported between
CYP1A1*2A and *2B and an increased risk of developing leukemia (Sinnett 2000, Bowen
2003). However, this association was not observed in a case-controlled study with 550
leukemia patients (Roddam 2000). Still another study by Krajinovic et al. (2002a)
reported that the CYP1A1*2A variant can increase the risk of leukemia and is associated
with an unfavorable outcome in children with ALL. In their study of 320 patients treated
with the Dana Farber Cancer Institute (DFCI) ALL protocol, sixty-four patients
experienced an event, defined as relapse or death from disease during or after completion
of therapy. The presence of at least one CYP1A1*2A allele was associated with an
increased of relapse risk, Hazard Ratio (HR) = 2.3 (95% CI: 1.2-4.9). This study cohort
included patients in the different risk groups whom were treated with various protocols.
The current dissertation research sought to collect some data that could be evaluated for
an association between CYP1A1*2B and the risk of disease relapse in standard-risk ALL.
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3.1.2. CYP3A4 and CYP3A5
The human CYP3A locus is located at 7q21.1 and consists of 4 function genes and
3 pseudogenes (Gellner 2001). The functional genes are CYP3A4, CYP3A5, CYP3A7, and
CYP3A43. Of the cytochrome P450 superfamily, the CYP3A subfamily is the most
important for drug-metabolism, accounting for 60% of P450 enzymes in the liver and
intestines (Danielson 2002). Thus far, polymorphisms in CYP3A4 and CYP3A5 are the
most studied in hematologic malignancies. Most chemotherapeutic agents are substrates
for CYP3A, including vincristine, cyclophosphamide, and epidophyllotoxins (Garte,
1998). The CYP3A4*1B polymorphism (-392A>G substitution), located in the regulatory
region of the gene, alters the transcriptional efficiency of CYP3A4 and impacts its overall
metabolic activity (Rebbeck 1998). However, its relevance for drug metabolism remains
unclear (Hesselink 2004). On the other hand, the CYP3A5*3 and CYP3A5*6
polymorphisms induce splice site variants that substantially decrease functional levels of
CYP3A5 compared with the wild type alleles (Kuehl 2001). Some studies have shown a
significant association between CYP3A4*1B/CYP3A5*3 and treatment-related leukemia,
drug-induced toxicities, and higher etoposide clearance (Felix 1998, Kishi 2004 and
2007). Felix reported a protective effect, Odds Ratio (OR) = 0.09 (95% CI 0.01-0.87), of
the CYP3A4*1B allele on secondary leukemia risk in a group of 99 de novo and 30
secondary leukemia samples. In contrast, Aplenc et al. (2003) found no statistically
significant impact of these 3 SNPs (CYP3A4*1B, CYP3A5*3, or CYP3A5*6) on disease
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prognosis in 533 cases of childhood ALL. An association between CYP3A4*1B and
CYP3A5*3C polymorphisms and a decreased risk of vincristine-associated peripheral
neuropathy, however was reported (Aplenc et al. 2003).

3.1.3. CYP2B6
The CYP2B6 gene is located at 19q13.2 and is highly polymorphic. CYP2B6
accounts for approximately 3-5% of total microsomal cytochrome P450 protein in the
liver and is also expressed in intestine, kidney, and brain (Gervot 1999). Several
polymorphisms have been reported for CYP2B6. The 1459C >T polymorphism
(Arg487Cys), termed *5 allele, corresponds to lower CYP2B6 protein levels when
compared with the wild-type allele (Lang 2001). Decreased enzymatic activity should
lead to decreased active metabolites, therefore inferior response to therapy and fewer
toxic side effects. Cyclophosphamide (CP) is a cytotoxic drug widely used in the
treatment of a variety of malignancies. CP is a prodrug requiring bioactivation to form
phosphamide mustard, which forms a strong bond with DNA, consequently inhibiting
both DNA replication and cell division, and ultimately leading to cell death (Sladek
1988). Various cytochrome P450 enzymes have been demonstrated to be involved 4hydroxylation of CP in humans (illustrated in Figure 3.5). Both CYP2B6 and the
previously discussed CYP3A4 are involved in the metabolic activation of the pro-drug
cyclophosphamide. CYP2B6 has higher affinity for the substrate and metabolizes the CP
by producing an active 4-hydroxy form, while CYP3A4 is responsible for the N-

48

dechloroethylation of the drug to yield chloroacetaldehyde - a neurotoxin, which is
responsible for some of the serious side effects of chemotherapy (Huang 2000). The
primary metabolite, 4-hydroxycyclophosphamide, is in equilibrium with its open-ring
tautomer (aldophosphamide) that undergoes chemical decomposition to form
phosphamide mustard (a bifunctional DNA alkylator and the ultimate cytotoxic
metabolite) and acrolein (Fleming 1997, Yu 1999) (Figure 3.5). Cyclophosphamide has a
relatively narrow therapeutic index, and adverse effects include cardiotoxicity,
nephrotoxicity, and myelosuppression. Studies have demonstrated wide inter-individual
variation in the metabolism of cyclophosphamide in pediatric populations (Yule 1995).
This makes a strong argument for studying the effect CYP2B6 polymorphisms on drug
response in childhood ALL.

3.1.4. GST
Glutathione-S-Transferases (GSTs) comprise a family of Phase II metabolic
enzymes. GSTs function as dimers by catalyzing the conjugation of electrophilic
substrates to glutathione. They are divided into eight classes, α through ө, based on their
amino acid sequence and immunoreactivity (Hayes 1999). The GSTM1, GSTP1 and
GSTT1 genes are members of the GST family and are located at chromosomal positions
1p13.3, 22q11.23 and 11q13 respectively. The most common polymorphisms include
complete deletions of the GSTM1 and/or GSTT1 gene which are termed ‘null’ alleles as
well as two SNPs in GSTP termed GSTP1*B and GSTP1*C (Cotton 2000,
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Figure 3.5 Metabolism of Cyclophosphamide. After cyclophosphamide administration,
approximately 70-80% of the dose is converted into 4-hydroxycyclophosphamide
(4OHCP) by various Cytochrome P450 enzymes including CYP2B6, 2C9, 2C19, 3A4,
and 3A5, with CYP2B6 displaying highest 4-hydroxylase activity. 4OHCP is in
equilibrium with its open-ring tautomer (aldophosphamide) which undergoes chemical
decomposition to form phosphamide mustard (a DNA alkylator and the ultimate
cytotoxic metabolite) and acrolein. 4OHCP and phosphamide mustard are detoxified by
gluthione S-transferase (GST) to form 4-gluthionycyclophosphamise and
digluthionycycyclophosphamide, respectively. This figure was adapted from Ekhart
(2008).
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Hayes 2000, Agundez 2008). GST enzymes are involved in the detoxification of various
exogenous substances, including chemotherapeutic agents (Tew 1994). Numerous studies
have investigated the correlation between different GST genotypes (GSTM1, GSTT1, and
GSTP1) and the susceptibility to various cancers (e.g., lung, bladder and breast cancer) to
treatment (Nazar-Stewart 1993, Nebert 1996). Some of these studies have shown an
increased risk of cancer for individuals with specific GST genotypes – an outcome
thought to be due to lowered enzyme activity. GSTM1 and GSTT1 null genotypes lead to
an absence of enzyme activity. The GSTP1*B polymorphism is characterized by a single
nucleotide 313A>G substitution in exon 5 which results in an amino acid change from
isoleucine to valine. This mutation causes steric hindrance at the substrate-binding site of
the enzyme thereby resulting in lower enzyme activity. Zielinska et al. (2005) recently
assessed the role of GST variants in urinary excretion of unchanged ifosfamide and its
side-chain metabolite. Specifically, they examined the levels of nephrotoxicity and
neurotoxicity in 76 children who were treated with ifosfamide for different childhood
neoplasms. They found that an individual’s response to ifosfamide was associated with
their GSTP1 genotype. One study also demonstrated a protective effect of GST
polymorphisms on relapse risk (Stanulla 2000). They reported a study of 64 pair of
relapsed and non-relapsed patients from BFM-86 and BFM-90 ALL trials. The GSTM1
and GSTT1 null genotypes were associated with a protective effect on leukemia relapse,
OR = 0.5 (95% CI 0.23-1.07) and OR = 0.36 (95% CI 0.13-1.23). The homozygous
GSTP1*B (i.e., Val105/Val105) genotype was noted to convey a similar protective effect,
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OR =0.33 (95% CI 0.09-1.23). However, a similar study from St. Jude Research Hospital
(SJCRH) did not observe a statistically significant impact for GST genotypes (Chen
1997). They analyzed the GSTM1 and GSTT1 genotypes and disease-free survival in 161
of 525 patients enrolled in the SJCRH Total XI, Total XII and Total XIIIa ALL
protocols. No association between GST genotypes and relapse risk was observed,
although a subset analysis demonstrated that the GSTM1 null genotype was associated
with a decreased risk of CNS relapse (98% vs. 94%, p= 0.054). As a cautionary note,
however, these studies used ALL patients with different treatment regimens; including
high-risk protocols.

3.2.

Drug response Pathways
Methotrexate (MTX) is a major component in the intensification and maintenance

phases of childhood ALL therapy across cooperative group trials (Chabner 2001). MTX
is a folate antagonist which competitively inhibits dihydrofolate reductase. This leads to
impaired regeneration of tetrahydrofolate from dihydrofolate due to a lack of folate
coenzymes and suppression of folate-dependent syntheses of DNA and RNA precursors
as show in the Figure 3.6. This inhibition of nucleic acid synthesis results in cellular
death. MTX cytotoxicity is also exerted through direct inhibition of enzymes associated
with purine and pyrimidine synthesis (Calver 1999). While highly effective in eradicating
leukemic cells, MTX is associated with significant gastrointenstinal, hepatic,
neurological, or hematological toxicities as well as general immune suppression. For this
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reason, dosing based on MTX pharmacogenetics plays an important role in high-dose
MTX therapy. High-dose infusion of MTX remains an important aspect of ALL therapy.
The advantage of this practice in high-risk ALL is still being investigated in the current
COG trials. It was shown to be beneficial in ALL patients with testicular disease. Several
studies from St. Jude Children Research Hospital have demonstrated good outcome by
individualizing the MTX dosage according to patient’s ability to clear the drug (Evans
1997 and 1998). Dosing adjustment is still part of St. Jude Total therapeutic protocols
today. Unfortunately, individualizing MTX dose is not always a feasible option for
patients treated elsewhere.

3.2.1. 5,10-methylenetetrahydrofolate reductase
The 5,10-methylenetetrahydrofolate reductase (MTHFR) is located at
chromosomal position 1p36.3 with 11 exons that span 13.5 Kb. MTHFR is a key enzyme
for intracellular folate homeostasis and metabolism. MTHFR catalyses the irreversible
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in the folate
metabolism pathway. The 5-methyltetrahydrofolate is a major circulating form of folate
which provides a methyl group for the methylation of homocysteine to methionine which
is required for nucleic acid methylation (Matherly 1996). The SNPs, MTHFR 667C>T
and 1298A>G have been associated with decreased MTHFR activity and increased levels
of homocysteine (Frosst 1995, Weisberg 1998, van der Put 1998). A change in reduced
folate pool, derived from MTHFR activity, may significantly affect patient response to
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antifolate therapy. Several groups have reported a protective effect of these
polymorphisms on leukemia susceptibility risk (Franco 2001, Alcasabas 2008).
Conversely, reduced MTHFR activity has been linked to a higher risk of relapse and
disease progression. Krajinovic et al. (2004) investigated the role of the MTHFR 667C>T
and 1298A>G polymorphisms in 201 patients treated on Dana Farber Cancer Institute
protocols for standard, high and very high risk ALL. The results showed that patients
with the MTHFR 667T/1298A haplotype had an increased risk of relapse, HR = 2.2 (95%
CI 1.0-4.7). Moreover, the effect of a thymidylate synthase (TYMS) triple repeat
(associated with increased TYMS levels) combined with the MTHFR 667T/1298A
haplotype demonstrated a highly significant reduction of EFS, HR = 9.0 (95% CI 1.042.8). Aplenc et al. (2005) presented the findings from the Children's Cancer Group
CCG-1891 trial, a national intermediate-risk ALL study involving 137 participating
institutions. Intermediate-risk patients between 1 and 10 years of age at diagnosis with
initial WBC counts of <5 X 104/μl. The treatment had age-adjusted intrathecal therapy
with weekly MTX (20 mg/m2) during the maintenance phase. An adverse event was
defined as leukemic relapse at any site. Controls were defined as patients that remained
with continuous remission with <5% leukemia blasts in a bone marrow aspirate. The
study set include 520 (43%) patients who had available samples that yielded DNA
adequate for genotyping. This sample set consisted of 124 relapsed and 396 non-relapsed
patients. It was reported that the MTHFR 677C>T variant allele showed a statistically
significantly association with leukemia relapse, χ2 = 4.38, P = 0.036. The association
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remained significant (HR = 1.82 (95% CI 1.16-2.84)), when controlling for important
covariates, and was found to be more predictive of relapse than other factors. While these
are the two biggest studies on pediatric ALL to date, other groups have found no
statistically significant effect (Rocha 2005, Chiusolo 2007). The wide range of results in
the treatment response with respect to MTHFR polymorphisms may reflect differences in
the treatment backbone of the protocol and dose adjustments made in some cases to limit
toxicity (SJCRH protocols).

3.2.2.

Thymidylate synthase
The thymidylate synthase gene maps to chromosomal position 18p11.32 and

contains 7 exons encoded across a 15.9 Kb genomic region (Kaneda 1990). TYMS is an
essential enzyme for cellular proliferation. It catalyzes the transformation of
deoxyuridine-5’-monophosphate (dUMP) to 2’-deoxythymydine-5’-monophosphate
(dTMP) which is an essential substrate for DNA replication. TYMS is an important
target for methotrexate, which forms a stable complex with TYMS and folate cofactors to
prevent DNA synthesis (Marsh 2001). The TYMS gene has a common length
polymorphism characterized by the presence of 28-base pair tandem repeats (TR) in the
5’ – untranslated region (5’-UTR). There are three predominant genotypes associated
with the TYMS gene: 1) homozygous with two TR (2R/2R); 2) homozygous with three
TR (3R/3R); and 3) heterozygous with both alleles (2R/3R). Increased TYMS mRNA
expression and enzyme activity are associated with a greater number of tandem repeats
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(Horie 1995, Kawakami 1999, Pullarkat 2001). Individuals who were homozygous for
the TR (3R/3R) were found to have a 4-fold greater relapse risk (OR = 4.1 (95% CI 1.99.0). This finding was confirmed in a subsequent investigation by the same research
group at the same institution (Krajinovic 2002 and 2005). Two studies also examined the
combined effects of multiple polymorphisms in several candidate genes in children with
ALL who were treated using the DFCI or SJCRH Total XIIIb protocols. They
demonstrated that patients who carried the 3R/3R genotype had a poorer outcome than
patients with fewer TR genotypes (Costea 2003, Rocha 2005). In contrast to these results,
however, other investigators have not been able to demonstrate similar associations
(Lauten 2003, Pakakasama 2007). Lauten et al. (2003) assessed the 2R/3R genotype in a
case-controlled study of 80 patients on the ALL BFM-86 and BFM-90 protocols. All
patients were classified as standard or intermediate risk, and received identical
cumulative MTX doses of 20g/m2 (5 g/m2 X 4 doses). They showed an OR = 1.1 (95% CI
0.70-2.98) for 3R/3R genotype. These discordant findings are likely due to the
heterogeneity of the study groups and their treatment protocols. Interestingly, there were
significant differences in wild type and heterozygous frequencies between these two
studies. One explanation for this could be due to preferential allele amplification in
archived specimens (Miller 2002).
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Figure 3.6 The folate pathway. This is a simplified schematic representation of the most
important gene products involved in methotrexate (MTX) treatment response. MTX
enters the cell through the reduced folate carrier. Its main intracellular target is
dihydrofolate reductase (DHFR), inhibition of which results in accumulation of
dihydrofolate (DHF) and depletion of cellular folates. MTX is a substrate for intracellular
folypolyglutamate synthetase (FPGS), which catalyses the formation of MTXPG s , which
then inhibits multiple target enzymes. This figure was adapted from PharmGKB (2004).
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3.3.

t(12;21)(p12;q22) in Acute Lymphoblastic Leukemia
The ETV6/RUNX1 (formly TEL/AML1) gene rearrangement results from a

cryptic, balanced, reciprocal chromosomal translocation, t(12;21)(p12;q22). This is the
most frequently occurring genetic abnormality seen with childhood ALL (Shurtleff 1995,
Romana 1995a) and it is associated with a favorable treatment outcome (McLean 1996,
Rubnitz 1997 and 1999).
The ETV6 gene (previously known as TEL) was first cloned in 1994 and is a
member of the ETS family of transcription factors whose protein product is a nuclear
phosphoprotein (Golub 1994 and 1997). It was subsequently found to be fused with
RUNX1 (previously known as AML1) in many cases of pediatric ALL (Golub 1995,
Romana 1995b). This gene rearrangement disrupts the ETV6 gene at the N terminus and
fuses the helix-loop-helix (HLH) domain, inframe, to nearly all of RUNX1, including its
DNA-binding Runt homology domain and its C-terminal transactivation region (see
Figure 3.7).
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Figure 3.7 Schematic representation of the TEL/AML1 gene rearrangement. Source: The
figure was modified from Rubnitz et al. (1999).
Numerous studies have been published regarding the prognostic significance of
the ETV6/RUNX1 fusion gene with divergent results. Early studies showed excellent
outcome. Both DFCI and St. Jude groups reported a favorable outcome for patients with
ETV6/RUNX1 (100% 8-year EFS and 92% 5-year EFS respectively). However, reports
from the BFM groups showed that as many as 25% of relapsed patients carried the
ETV6/RUNX1 fusion gene (McLean 1996, Shurtleff 1995, Harbott 1997, Seeger 1998).
Later, studies from the Pediatric Oncology Group (POG) and DFCI supported the
excellent outcome for patients carrying ETV6/RUNX1 fusion gene (Loh 1998, Pui 2000).
Since all treatment protocols were based on the risk-stratification strategies, the
heterogeneity of results may reflect the intensity of the treatment protocol and the
assignment of patients to the risk group at diagnosis. For example, nearly half of the
ETV6/RUNX1-positive patients in the first report from the DFCI study received intensive
therapy (McLean 1996). This difference might potentially explain the improved outcome
in this group of patients. Most recently, a DFCI prospective analysis of ETV6/RUNX159

positive patients treated on their 95-01 protocol found an ETV6/RUNX1 prevalence of
26%, with a median follow-up of 5.2 years (Loh 2006). The 5-year EFS for
ETV6/RUNX1-positive patients was 89% compared with 80% for ETV6/RUNX1-negative
pre-B ALL patients (P = 0.05). The 5-year Overall Survival (OS) rate was 97% among
ETV6/RUNX1-positive ALL patients compared with an OS of 89% among
ETV6/RUNX1-negative ALL patients (P = 0.03). This is a result which confirms their
previous findings.
Interestingly, among all the studies reviewed above, the unified pattern of relapse
in ETV6/RUNX1-positive patients demonstrated that these patients tend to relapse long
after therapy and remain sensitive to the same chemotherapy after relapse. This finding
prompted the investigators to speculate about the origin of the relapsed clone. Using
microsatellite markers, immunoglobulin and T-cell gene rearrangement analysis as well
as fluorescent in situ hybridization techniques, Ford, et al. (2001) elegantly demonstrated
that the clonal origin of two patients with late relapse was distinct from the initial
leukemic clones despite the presence of the ETV6/RUNX1 fusion transcript in the primary
and relapsed leukemic cells. These investigators hypothesized that in some
ETV6/RUNX1-positive relapsed patients most, but not all, the leukemic cells are
eradicated by the initial therapy; then a second, independent transformation event occurs
which gives rise to new ETV6/RUNX1-positive leukemic cells.
Most studies demonstrate that ETV6/RUNX1-positive patients have excellent
treatment outcome compare to the ETV6/RUNX1-negative patients. Despite these
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findings, international collaborative groups have not been able to reach a consensus
regarding the use of a patient’s ETV6/RUNX1 status as a prognostic indicator.
Based on the numerous supportive studies that have been reported to date, it
would be unreasonable to completely ignore the potential for host genetic variation in to
impact the chemo-sensitivity and treatment outcome. In the current research, therefore,
an attempt to further evaluate the possible association between treatment outcome and
ETV6/RUNX1 fusion transcript status in a somewhat “homogenous” group of ALL
patients.

Summary: A wealth of research data support the view that genes involved in drug
metabolism and genes that encode drug targets influence response to therapy and disease
outcome in patients with ALL. It is important to recognize that these genetic variations
may significantly associate with a specific drug response phenotype in the context of one
treatment regimen but not in other regimens for the same disease. To evaluate the role of
variants in drug-metabolism and drug-target genes in predicting therapeutic outcome, the
current doctoral research study was conducted with the aim of assessing potential
associations between disease remission, disease relapse rates and polymorphisms in the
drug metabolism genes CYP1A1, CYP2B6, CYP3A4, CYP3A5, GST, MTHFR, and TYMS.
A total of 125 patients with standard-risk ALL treated at The Children’s Hospital,
Aurora, Colorado served as the study population. This investigation has provided a
unique opportunity to assess host genetic variations relative to treatment outcomes
(specifically relapse) in a cohort of NCI-defined standard-risk ALL patients, all of whom
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presented with defined patient and tumor characteristics and who underwent similar
chemotherapeutic regimens.
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Chapter 4
Methods

4.1.

Description of Study Population
Children with standard risk ALL, defined as age between 1 and 10 years at

diagnosis and initial WBC count of <5 x 104/μl, treated at The Children’s Hospital
between 1993 and 2005 were retrospectively included in this study.
The Center for Cancer and Blood Disorders at the Children’s Hospital of Denver
has a COMIRB-approved research protocol to collect diagnostic peripheral and bone
marrow samples from newly diagnosed patients with leukemia. Patient cell bank samples
had been previously collected in a de-identified manner and leftover clinical DNA
samples were de-identified. This study was approved by COMIRB and the University of
Denver IRB. There are no plans for further enrollment for the current study.

4.1.1. Inclusion criteria
Patients who met the age and WBC criteria as well and for whom bone marrow or
peripheral blood samples at initial diagnosis were available along with a record of
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treatment outcome were included in this study. All samples were obtained from the
COMIRB-approved cell bank in the Center for Cancer and Blood Disorders and the
Molecular Diagnostic Laboratory at The Children’s Hospital. Finally, to be accepted for
inclusion in the current study, it was required that all samples had been collected per
COMIRB 04-1041 approved protocols.

4.2.

Nucleic Acid Extraction
Genomic DNA was extracted from peripheral blood or bone marrow aspirate

using the Gentra PureGene Blood Kit (Gentra, Minneapolis, MN) following the
manufacturer's instructions. Briefly, patient bone marrow (or peripheral blood) samples
were collected in EDTA-tubes for routine clinical testing. An aliquot of 300 μl of bone
marrow (or peripheral blood) was incubated for 10 minutes at room temperature in 900 μl
of RBC lysis solution. White blood cells (WBCs) were then collected by centrifugation
at 13,000 x g. for 20 seconds. The supernatant was carefully removed to avoid disturbing
the WBC pellet and 600 μl of Cell Lysis Solution was added to the tube. The WBC
pellet was resuspended by pipetting up and down to lyse the cells. When no visible cells
remained, 200 μl of Protein Precipitation Solution was added to the cell lysate tube. The
tube was then vigorously vortexed for 20 seconds and centrifuged for 15 minutes at
13,000 x g to pellet the protein. The supernatant containing the DNA was transferred to a
clean 1.5 ml microfuge tube containing 600 μl of 100% isopropanol. The tube was
inverted 20 – 30 times then centrifuged at 13,000 x g. for 5 minutes. The precipitated
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DNA was then visible as a small white pellet. The supernatant was discarded and the
pellet was washed with approximately 300 μl of 70% ethanol by inverting the tube
several times. The tube was centrifuged at 13,000 x g for 15 minutes. The ethanol was
poured off and the tube was left open at room temperature for 5 – 10 minutes (taking care
not to over dry the DNA pellet). The DNA pellet was then resuspended in approximately
50 μl of DNA Hydration Solution (10 mM Tris (pH 7.6) and 1 mM EDTA), vortexed for
5 seconds at medium speed and then incubated at 65 0C for 15 – 30 minutes to accelerate
rehydration. The rehydrated DNA was allowed to sit at room temperature overnight to
ensure complete the rehydration. The DNA concentration was measured using the
NanoDrop spectrophotometer and all DNA samples were then diluted with DNA
Hydration Solution to the final working concentration as 50 ng/μl. The working DNA
solution was stored at – 70 0 C until analyzed. Detailed information on the DNA
extraction technique may be found in Appendix 1.

4.3.

Genetic Polymorphism Detection
Nine SNPs and two genetic deletion/duplication mutations in the Phase I and II

metabolism enzymes (CYP and GSP respectively) and drug-target (MTHFR and TS)
genes were chosen for genotyping based on the important roles they played in the
pharmacokenetics and pharmacodynamics of chemotherapeutic drugs. TaqMan®
(Applied Biosystems (ABI), Foster City, CA) genotyping techniques were utilized for
SNP genotyping. Polymerase chain reaction (PCR) and argarose gel electrophoresis were
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employed for gene deletion or duplication detection. The genetic polymorphisms content
sequences are presented in Table 4.1. The details of the detection procedures are
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rs, dbSNP identifier; ABI, Applied Biosystems

Table 4.1 Content sequences for the genetic polymorphisms

described below.

4.3.1. Genotyping by TaqMan® Drug Metabolism Genotyping Assays
TaqMan® Drug Metabolism Genotyping Assays were used to detect GSPT1,
CYP3A5, CYP2B6, and CYP1A1 polymorphisms. The assay are based on the 5’ nuclease
chemistry for amplifying and detecting specific genetic polymorphisms in DNA samples.
These assays were developed using ABI’s bioinformatic assay design process, and
genomic information from public SNP databases and public genome assemblies. These
assays are designed and optimized to work with TaqMan® Universal PCR Master Mix
(ABI, Foster City CA) and only 3 to 20 ng of DNA is required for each reaction. Each
assay contains sequence-specific forward and reverse primers that amplify the
polymorphic sequence of interest; one probe labeled with a VIC® reporter dye and a nonfluorescent quencher (NFQ) dye to detect the “Allele X” sequence and; a second probe
labeled with a 6-FAM™ reporter dye and a NFQ dye to detect the “Allele Y” sequence.
During PCR, each TaqMan® probe anneals specifically to its complementary sequence
between the forward and reverse primer sites. AmpliTaq Gold® DNA polymerase extends
the primers bound to the DNA template and cleaves only the probe that are bound to the
target. Cleavage separates the reporter dye from the quencher dye, resulting in increased
fluorescence by the reporter molecule. By detecting the increase in fluorescence signal, it
is possible to determine which alleles are present in the sample. Even single nucleotide
mismatches between a probe and the target sequence alter the efficiency of probe binding
to the target, which in turn reduces the amount of reporter dye cleaved from a quenched
probe. Figure 4.1 shows the principle of this assay. A substantial increase of only VIC®
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Figure 4.1 Principle of TaqMan® Chemistry. Allelic discrimination probes are labled
with VIC® dye at the 5’ end of the allele 1 probe and 6-FAM™ dye at the 5’ end of allele
2 probe. A NFQ and a MGB are linked to the 3’ end of each probes. During PCR, Taq
DNA polymerase is more likely to displace a mismatched probe without cleaving it.
Conversly, Taq DNA polymerase cleaves a probe that is hybridized (matched) to the
target temple, reulting in an increased flurescence by the reporter dye. The uncleaved
probe (mismatched) will not generate an increased fluorescence due to the presence of
quencher dye in a close proximity. Thus, an increased fluorescence signal (6-FAM™ or
VIC®) during PCR amplification indicates which allele is present in the sample.
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Figure 4.2 Workflow of TaqMan® genotyping. The above is a schematic representation of the
workflow involved in the TaqMan® genotyping. From Left to right: reaction plate was prepared
with reaction mix and template DNA, followed by PCR amplification set up with an new plate
read (Pre-Read) was performed, then a real-time PCR was performed, followed by the post-read
run whcih the SDS software automatically subtrates the baseline fluoresence determined at the
pre-read and allele calls were assigned by the SDS software.
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dye signal indicates homozygosity for Allele 1 and vise versa a substantial increase of
only 6-FAM™ signal will indicate homozygosity for Allele 2. Heterozygosity for Allele
1 and 2 will be represented by the increase in both VIC® and 6-FAM™ signals. An
“allelic discrimination experiment” is constructed according to the Applied Biosystems
7500 “Allelic Discrimination: Getting Started Guide”. Figure 4.2 illustrates the complete
process for an allelic discrimination experiment.
Each genotyping reaction contains 12.5 μl of 2X TaqMan® Universal PCR Master
Mix (UMM), 1.25 μl of Assay Mix (primers and probes), 10.25 μl of DNase-free water,
and 1.0 μl of sample DNA (50 ng/μl). The UMM, Assay Mix and DNase-free water were
combined in a microcentrifuge tube to create a master mix (MM). The MM was flicked
and inverted several times to mix the contents. Aliquots of 24.0 μl of MM were then
pipetted into the required number of wells on an optical 96-well plates (ABI, Foster City,
CA). Template DNA (1 μl of 50 ng/μl stock) was then added to each well and the
reaction plate was sealed with optical caps. Two, “no template” negative controls (Dnasefree water) were included in each assay. The ABI 7500 Real-Time PCR System was
slected to perform all allele discrimination experiments. This system allows real-time
analysis of PCR, which provides for greater assay accuracyand is helpful for
troubleshooting. The thermal cycling conditions employed are shown below.
Taq Gold® polymerase
activation

PCR
(50 cycles)

HOLD

Denature

Anneal/Extend

10 min at 95 oC

15 sec at 92 oC

90 sec at 60 oC
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An Allelic Discrimination (AD) Plate Document was set up on the ABI 7500 Real-Time
PCR System in which 6-FAM™ and VIC® were selected as detectors for the wildtype
and mutant alleles, respectively. The amplification run was then performed according to
manufacturer’s instruction (refer to manufacturer’s instructions for details). All data
generated during the run were saved to the AD plate document specificed previously.
The AD data collected during the run were then analyzed by the 7500 SDS software.
Briefly, the raw data were converted the raw were organized in terms of fluorescence
signal vs. filters. The SDS software plots the results from the AD run on a scatter plot of
Allele X vs. Allele Y. Each well of the reaction plate is represented an “X”
(Undetermined) on the plot as shown in Figure 4.3. The clustering of points can vary on
the plot due to differences in the content of reporter dye fluorescent intensity after PCR
amplification. Allele calls are then assigned by selecting “Automatic Allele Calling”
under the “Analysis Setting” and then selecting the “Reanalyze” tab. Samples are then
grouped on the plot as “Allele X”, “Allele Y”, “Both Alleles X & Y”, “Undetermined”
and “NTC” (illustrated in Figure 4.4). The allele calls for each sample well are then
listed in the Call column (Figure 4.5) (refer to manufacturer’s instructions for details).
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Figure 4.3 Allelic discrimination cluster plot. After a post-read, the 7500 SDS
software display a scatter plot of Allele X vs. Allele Y with each wells
represented by an X. The X represents the ratio of dye fluorescence intensity from
Allele X dye and/or Allele Y dye after PCR amplification. The horizontal axis
(Allele X) and vertical axis (Allele Y) indicate dye fluorescence intensity.

Figure 4.4 Allelic discrimination post-read plot. After 7500 SDS software
analysed the ratio of raw fluorescence data, a post-read plot was displayed. A genotype
was assigned for each sample in each well according to the relative dye fluorescence
intensity.
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Figure 4.5 Allelic discrimination genotyping reports. The post-read data can be also
displayed as a report form. (a) displays the genotyping results in a table format, (b)
represents the allele calls listed as the name of the dye-related probes, (c) the user-defined
column can be used to add comments.
4.3.2. Genotyping by TaqMan® Genotyping Assays
CYP3A4, MTHFR 667, and MTHFR 1298 polymorphisms were genotyped using
laboratory developed assays with TaqMan® chemistry, samples handing steps and data
analysis methods as described in the preceeding section. The forward primer, reverse
primer, wildtype allele probe (VIC® labeled), and mutant allele probe (6-FAM™ labeled)
were selected from the National Cancer Institute’s SNP500 database
(http://snp500cancer.nci.nih.gov). Primer and probe sequences are listed in Table 4.2.
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Table 4.2 Primers and Probes for CYP3A4 and MTHFR Genotyping

4.3.3. Genotyping for TYMS, GSTM1, and GSTT1
Genotyping for the TYMS tandem repeats was performed by polymerase chain
reaction assay as previously described with modification (Hishida et al., 2003). Briefly,
the reaction consisted of 2 μl of (50 ng/μl) genomic DNA, 2.5 μl of GeneAmp® 10X PCR
Gold Buffer with 15 mM MgCl 2 (ABI, Foster City, CA), 0.5 μl of DMSO (Sigma, MO),
1 μl of 10 μM forward primer, 1 μl of 10 μM reverse primer, 2 μl of 2.5 mM dNTPs, 0.2
μl of 5U/μl AmpliTaq Gold® and 16.8 μl DNase-free water. The sequence of the forward
primer was (5’-CGT GGC TCC TGC GTT TCC-3’) and the sequence of the reverse
primer was (5’-GAG CCG GCC ACA GGC AT-3). Amplification was performed in a
Veriti 96 Well Thermal Cycler (ABI, Foster City, CA) with initial denaturation at 95oC
for 5 minutes followed by 45 cycles of 95oC for 15 seconds, 60oC for 20 seconds and
72oC for 20 seconds. There was also a final elongation step at 72oC for 10 minutes.
Amplified PCR products were electrophoresed through a 3% agarose gel in 1X TrisAcetate-EDTA (TAE) buffer (Qiagen, Valencia, CA) and visualized with ethidium
bromide staining to detect the 2R (210 base pair; bp) and 3R (238 bp) alleles as illustrated
in Figure 4.6.
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Figure 4.6 Genotyping for TYMS tandem repeats. PCR products were separated by
electrophoresis to determine genotypes. The 2R and 3R alleles were identified by a band
of 210 and 238 bp, respectively, as indicated. Lane M indicates a DNA ladder; Lan1 and
2 represent 2R/2R genotype; Lane 4, 7, and 8 represent 2R/3R genotype; Lane 3, 5-6, 912 represent 3R/3R genotype; Lane 13 represents no template control.
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GSTT1 and GSTM1 gene deletions, designated as null allels, were identified by
PCR amplification as previously described (Spurdle et al., 2001), using primers located
within the GSTT1 and GSTM1 genes to detect the presence of these gene sequences. A
5’-untranslated region of the estrogen receptor (ER) gene was amplified as a positive
amplification control to ensure a succesful amplification reaction. Primer sequences and
product sizes are listed in Table 4.3. Each PCR reaction took place in a 25 μl reaction
volume which contained 100 ng of genomic DNA, forward/reverse primers (400 nM),
dNTPs (200 nM), 1X Gene- AMP® Gold PCR Buffer with 1.5 mM MgCl 2 , and 1 U
AmpliTaq Gold® (Applied Biosystems, CA). Amplification was performed in a Veriti 96
Well Thermal Cycler (ABI, Foster City, CA) with initial denaturation at 95oC for 5
minutes followed by 45 cycles of 95oC for 15 seconds, 61oC for 20 seconds and 72oC for
20 seconds. There was also a final elongation step at 72oC for 10 minutes. Amplified
PCR products were electrophoresed through a 3% agarose gel in 1X TAE buffer
(Qiagen, Valencia, CA) and visualized with ethidium bromide staining to detect the
GSTT1 and GSTM1 null alleles as illustrated in Figure 4.7. All reactions were expected
to show amplification of the ER positive amplification control (181 bp).The absence of a
114 bp or 131 bp fragment indicated GSTM1 or GSTT1 null genotypes, respectively.
Patient samples showing amplification of the target PCR products were defined as having
a non-null genotype.
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Table 4.3. Primer sequences used for PCR detection of GSTT1 and GSTM1 genotypes

A

M

1
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12

131 bp
B

114 bp
C

181 bp

Figure 4.7 Representative cases of GSTT1 and GSTM1 genotyping. Lane M indicates
DNA ladder. (A) GSTT1 genotyping examples. Lane 3 and 4 represent null genotypes
while the remainder of the lanes represent non-null genotypes. (B) GSTM1 genotyping
examples. Lanes 3, 5, 8, and 11 indicated non-null genotypes. (C) ER PCR products.
Lane 12 was a no-template control (water) and is used to indicate the absence of
contamination in the stock PCR reagents. Lane 4 indicates a double null genotype for
GSTM1/GSTT1.
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4.4.

Statistical Analysis
The primary outcome of interest in the current study was disease relapse. For

analysis of relapse risk, cases of relapse were defined as patients who experienced
leukemia relapse at any site. The event-free group was defined as those patients who
remained in continous remission (<5% lymphoblasts in bone marrow aspirate).
The majority of the 125 patients with standard-risk ALL yielded adequate DNA
for complete genotyping. The study set included 16 patients who experienced disease
relapse and 109 patients in continous remission. Statistical analyses were performed with
SAS/STAT software (SAS Institute Inc., NC) at the Colorado Biostatistics Consortium.
For statistical analyses, A p value less than 0.05 was considered significant.
Kaplan-Meier survival curve is the most common method to describe survival
characteristics. It tracks how many individuals have not experienced the event at a given
time or during a given time interval. The data is then plotted over the entire time of the
study. The survival curve represents an estimated probability (Y-axis) of surviving in a
given length of time (X-axis). This analysis allows estimation of survival over time.
Hazard, defined as the probability of the endpoint (e.g., leukemia relapse), is a mesure of
how rapidly the event occurs. The hazard ratio (HR) compares the hazards in two groups
(e.g., relapse and EFS) and is calculated with its 95% confidence interval. HR is a
estimate of relative risk of event.
Univariate analysis of 12 genotypes and disease relapse was performed with Chisquare or Fisher’s exact tests to compare the genotypes frequencies in the relapse and
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event-free groups. In order to estimate the relative risk of disease relapse, hazard ratios
(HRs) and 95% confidence intervals (CIs) were calculated using a logistic regression
model to evaluate the significance of differences in survival between the relapsed and
event-free survival groups. Life table estimates were calculated by the Kaplan-Meier
method and survival curves were generated for a graphical presentation of event-free
survival probabilities. Survival time was defined as the time between diagnosis and the
date of an event or last follow-up. A log-rank test was ultilized to compare time-torelapse values (Kaplan & Meier, 1958).
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Chapter 5

Results

A total of 125 patients with a diagnosis of standard-risk acute lymphoblastic
leukemia treated from 1998 through 2005 at the Center for Cancer and Blood Disorder at
The Children’s Hospital in Denver were included in this study. Standard-risk ALL was
defined according to NCI criteria based on age (1 – 9.99 years) and initial WBC count
(less than 50,000/μl) at diagnosis. Genotype frequencies are shown in Table 5.2. Among
this cohort, there were 72 (58%) males and 53 (42%) females which is comparable to the
national frequency for standard-risk ALL. There were 16 patients who had experienced
disease relapse and 109 patients who had remained event-free. This gives a 5-year EFS of
87.2% which is slightly better than the national average of 81.6% (p = 0.14) (Matloub,
2006). Patient ethnicity data were not collected because 91% of ALL patients treated at
The Children’s Hospital in Denver are of Caucasian ethnicity. Table 5.1 shows the ethnic
distribution among the ALL patients treated at The Children’s Hospital in Denver.
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Table 5.1 ALL patient distribution
Gender

Ethnic Categories
Females

Males

Total

Hispanic or Latino

9

12

21

Not Hispanic or Latino

55

74

129

64

86

150

American Indian/Alaska Native

2

2

4

Asian

2

3

5

Native Hawaiian or Other Pacific Islander

0

0

0

Black or African-American

2

3

5

White

58

78

136

64

86

150

Ethnic Categories: Total of All Subjects

Racial Categories

Racial Categories: Total of All Subjects

Note: These classifications are constructed according to “Revisions to the Standards for the Classification
of Federal Data on Race and Ethnicity” by the Office of Management and Budget (October 30, 1997).
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Table 5.2 Genotype frequencies distribution
Genotype

Relapsed
n (%)

EFS
n (%)

CYP 1A1

P1
0.473

AA

13 (86.7)

85 (78.7)

AG

2 (13.3)

23 (21.3)

GG

0 (0)

0 (0)

CYP 2B6

0.923

CC

13 (81.3)

85 (78.7)

CT

3 (18.7)

21 (19.5)

TT

0 (0)

1 (0.9)

CYP 3A4

0.888

AA

15 (93.8)

98 (90.7)

AG

1 (6.2)

9 (8.4)

GG

0 (0)

1 (0.9)

CYP 3A5_1

0.009

CC

15 (93.8)

108 (100)

CT

1 (6.2)

0 (0)

TT

0 (0)

0 (0)

CYP 3A5_2

0.460

AA

14 (87.5)

80 (74.1)

AG

2 (12.5)

24 (22.2)

GG

0 (0)

4 (3.7)

GSTP1_1

0.502

CC

15 (93.8)

90 (82.6)

CT

1 (6.2)

16 (14.7)

TT

0 (0)

3 (2.7)

GSTP1_2

0.680

AA

6 (37.5)

36 (33)

AG

6 (37.5)

53 (48.6)

GG

4 (25)

20 (18.4)
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Table 5.2 (continued)
Relapsed
n (%)

Genotype

EFS
n (%)

MTHFR 677

0.356

CC

7 (43.8)

40 (37.4)

CT

8 (50)

44 (41.1)

TT

1 (6.2)

23 (21.5)

MTHFR 1298

0.676

AA

7 (43.8)

60 (55.5)

AC

7 (43.8)

37 (34.3)

CC

2 (12.5)

11 (10.2)

GSTM1

0.144

present

12 (75)

59 (55.7)

null

4 (25)

47 (44.3)

GSTT1

0.662

present

14 (87.5)

89 (83.2)

null

2 (12.5)

18 (16.8)

TS tandem
repeat
2R/2R

5 (31.3)

27 (25.2)

2R/3R

9 (56.2)

48 (44.9)

3R/3R

2 (12.5)

32 (29.9)

0.348

TEL/AML1

0.096

Present
Not present

P1

0 (0)
16 100)

16 (15.1)
90 (84.9)

1. Chi-square test
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5.1. Phase I Drug-Metabolism Enzyme Polymorphisms
A total of 123 patient samples were successfully genotyped for the CYP1A1
(rs1048943) and CYP2B6 (rs3211371). Genotypic frequencies are shown in Table 5.3.
These are comparable to the published frequencies in the NCI SNP500. Among the 123
patient samples, 25 patients were found to be heterozygous for CYP1A1 and 2 of them
were in the relapsed group. No individuals who were homozygous for the mutant allele
were observed in this study cohort. There was no statistically significant difference
between the EFS group and the disease relapsed group with regard to genotypic
frequencies (P = 0.473, χ2). The CYP2B6 heterozygous genotype (CT) was found in 24
patients while the homozygous genotype (TT) was found in just 1 patient. A statistically
significant difference was not observed in the genotype distribution between the relapsed
group (CC, 81.3% and CT, 18.7%) and the EFS group (CC, 79.4%; CT, 19.5%; TT,
0.9%). The TT genotype was not observed in the relapsed group. This is likely due to its
low allele frequency.
A total of 124 patients were genotyped for CYP 3A4 (rs 2740574), CYP3A5 (rs
10264272), and CYP3A5 (rs776746). Genotypic frequencies are comparable to published
reports including the NCI SNP 500. There is no statistically significant difference
between the relapsed and EFS groups for the CYP3A4 (rs2740574) and CYP3A5
(rs776746) genotypes frequencies (p = 0.888 and 0.460, respectively). There is also no
statistically significant difference of risk of relapse (HR = 0.67, 95% CI = 0.09 – 2.80, P
= 0.70 and HR = 0.43, 95%CI = 0.10 – 1.90, P = 0.27 respectively). No CYP3A4 GG
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genotype was observed and the AG genotype was observed in only 1 patient and that
individual was in the relapsed group. In the EFS group, the AG genotype was found in 9
patients and the GG genotype was found in 1 patient.

5.2.

Phase II Drug-Metabolism Enzyme Polymorphisms
With regard to the glutathione S-transferase (GST) genotypes, four GST

polymorphisms were analyzed. They include 1) the coding region SNPs at codon 105
(rs1138272) defined as GSTP1 (C > T) and codon 114 (rs1695) defined as GSTP1 (A >
G), 2) as well as the GSTM1 and GSTT1 deletions. The homozygous deletions defined as
GSTM1 null and GSTT1 null lead to the absence of phenotypic enzyme activity.
The genotypic frequencies for the current study cohort were found to be consistent with
the published reports included in NCI SNP500. The genotype prevalence in the entire
study population was as follow: GSTP1 (rs 1138272) CC: 84.0 %; CT: 13.6%; TT: 2.4%.
No TT genotype was observed in the relapsed group. GSTP1 (rs1695) AA: 33.6%; AG:
47.2%; GG: 19.2%; GSTM1 present: 58.2%; GSTM1 null: 41.8%; GSTT1 present: 83.7%;
GSTT1 null: 16.3%. Table 5.4 shows the distribution of GSTM1, GSTT1 and GSTP1
genotypes in the EFS and relapsed groups and the association of these genotypes with the
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HRs were calculated for CYP1A1 CT vs. CC, CYP2B6 CT/TT vs. CC, CYP3A4 AG/GG vs. AA, CYP3A5
(rs10264247) CT vs. CC, and CYP3A5 (rs776746) AA/AG vs. GG, respectively. P*, P value was estimated
by chi-square test. HR: Hazard Ratio; CI: Confidence Interval; EFS: Event-Free Survival

Table 5.3 Analysis of CYP1A1, CYP2B6, CYP3A4, and CYP3A5 polymorphisms and risk of leukemia relapse

occurrence of disease relapse. In terms of the risk of disease relapse for the current study
cohort, the GSTM1 null genotype appeared to confer a 2.5-fold protective effect
compared to patients that were homozygous for the non-null condition. This apparent
protective effect, however, was not statistically significant (HR = 0.394; 95% CI = 0.127
– 1.2254, P = 0.107). Relative to the presence of the GSTT1 gene, the GSTT1 null
genotype was also associated with an apparent reduction in the risk of leukemia relapse.
This apparent effect, however, was not statistically significant (HR = 0.662; 95% CI =
0.150 – 2.915, P = 0.585). A 3-fold statistically non-significant difference in risk of
relapse (HR = 0.341; 95% CI = 0.045 – 2.581, P = 0.298) was associated the GSTP1
(rs1138272) CT & TT genotypes in comparison to the CC genotype. No association with
leukemia relapse was found for the GSTP1 (rs1965) polymorphisms. The HR for the GG
& AG genotypes compared to AA genotype was 0.828 (95% CI = 0.301 – 2.279, P =
0.715).
GST enzymes exhibited broad substrate specificity toward a variety of substances
(Tew 1994). Given the profound effect of GSTM1 and GSTT1 null genotypes (absence
of enzyme activity), the association of GSTM1 and T1 genotype combination with the
risk of leukemia relapse was investigated in this study cohort. Patients were grouped
according to their genotype as either: 1) GSTM1 or T1 showed a null genotype or 2) both
GSTM1 and T1 were present. The risk of relapse increased 2.7-fold when both GSTM1
and GSTT1 were present compared to when either GSTM1 or GSTT1 was a null genotype
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(HR = 2.7, 95% CI = 0.9 – 7.9, P = 0.063). This result approached but did not reach
statistical significance.

5.3.

Drug-Target Polymorphisms
Genotype distributions for the MTHFR and TYMS enzymes, which are the

critical components of the folate metabolic pathway, are shown in Table 5.5. Overall
genotype frequencies were as follow: The frequencies of MTHFR genotypes involving
the C/T polymorphism at nucleotide position 677 in the current study cohort were 38.2%,
42.3%, and 19.5% for the CC, CT, and TT genotypes, respectively. There was no
statistically significant association between the relapsed and EFS groups in regard to
genotype distribution. A slightly higher TT genotype was noted for the current study
cohort but the C and T allele frequencies were within the observed range of published
reports. The MTHFR 677 TT genotype was observed in 6.2% and 21.5% of patients
among the relapsed and EFS groups, respectively. This difference did not reach statistical
significance (P = 0.356, chi-square test).
The frequencies of MTHFR genotypes involving the A/C polymorphism at
nucleotide position 1298 in the current study cohort were 54.0%, 35.5%, and 10.5% for
the AA, AC, and CC genotypes, respectively. There was no statistically significant
difference regarding to the CC genotype distribution in the current study cohort which
showed a frequency of 12.5% and 10.2% in the relapsed and EFS groups respectively
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HRs were calculated with GSTP1 (rs1138272) CC/CT vs. TT, GSTP1 (rs1695) AA vs. AG/GG,
GSTM1 null vs. present, GSTT1 null vs. present, respectively. P*, P value was estimated by chisquare test. HR: Hazard Ratio; CI: Confidence Interval; EFS: Event-Free Survival

Table 5.4 Analysis of GSTP1, GSTM1 and GSTT1 polymorphisms and risk of leukemia relapse

(P = 0.676, chi-squred test). The MTHFR 1298 CC genotype showed a slightly increased
HR relative to the AA and AC genotypes (HR = 1.35, 05% CI = 0.307 – 5.962, P =
0.689) but this did not reach statistical significance.
The TYMS gene has a promoter enhancer region polymorphism in the 5’untranslated region, characterized by a double (2R) or triple (3R) 28-bp tandem repeat
sequence. As shown in Table 5.5, the genotype frequencies of genotypes involving this
TYMS polymorphism in the study cohort were 26.0%, 46.3%, and 27.6% for the 2R/2R,
2R/3R, and 3R/3R genotypes, respectively. This distribution is comparable to published
reports. Among the relapsed and EFS groups, the polymorphism distribution was 31.3%
and 25.2% for 2R/2R, 56.2% and 44.9% for 2R/3R, and 12.4% and 29.9% for 3R/3R
respectively. This difference was not statistically significant (P = 0.356, chi-squred test).
The 3R/3R patients had an apparent decreased risk of leukemia relapse when compared
to 2R/2R and 2R/3R genotypes in the study cohort (HR = 0.401, 95% CI = 0.091 – 1.767,
P = 0.227). This apparent difference, however, did not reach statistical significance.

5.4.

Combinational Analysis of CYP and GST Genotypes
CYP and GST genotypes may confer varying degrees of metabolic activities for

chemo-theraputic agents. For this reason, the potential association between CYPGSTM1/T1 combinations and the risk of leukemia relapse was investigated for the
current study cohort. Hence, the study cohort was grouped into three clinically pre92

defined “drug exposure groups” based on their known genotypes, as: 1) High-drug
exposure group, 2) Low drug-exposure group, and 3) Intermediate-drug exposure group.
Table 5.6 lists the features of these groups.
Table 5.7 lists the “drug exposure group” with regard to the risk of leukemia
relapse in the study cohort. Patients who were in the low-drug exposure group had a 2.2fold increased risk of relapse compared to the high-drug exposure group. When the highdrug exposure group was compared to the low and other-drug exposure groups, this
phenomenon remainded with a 2.4-fold increased risk of relapse for the low and otherdrug exposure groups compared to the high-drug exposure group. The Kaplan-Meier
survival curves reflected these differences in the EFS.
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HRs were calculated with MTHFR 677 TT vs. CT/CC, MTHFR 1298 CC vs. AC/AA, and TS 3R/3R vs.
2R/3R & 2R/2R respectively. P*, P value was estimated by chi-square test. HR: Hazard Ratio; CI:
Confidence Interval; EFS: Event-Free Survival

Table 5.5 Analysis of MTHFR 677 C /T, 1298 A/C and TYMS tandem repeat polymorphisms and risk of
leukemia relapse
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Table 5.6 “Drug Exposure Group” Features
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P*, P value was estimated by chi-square test. HR: Hazard Ratio; CI: Confidence Interval; EFS: EventFree Survival

Table 5.7 “Drug exposure group” and risk of leukemia relapse

Chapter 6

Discussion
Acute lymphoblastic leukemia (ALL) is the most common childhood malignacy.
Tremendous progress has been made in the therapeutic outcome of ALL over the last four
decades.The current cure rate routinely exceeding 80% in most collaborative groups (Pui,
2008 &2009). Standard-risk ALL has seen 6-year event free survival reach 82% with an
overall survival rate of 92% (Malempati 2007, Matloub 2006). Despite these successes,
the outcome of relapsed ALL remains poor and it is the most common cause of cancerrelated death in children. The 5-year overall survival estimate after bone marrow relapse
is approximately 24% (Gaynon 1998, Rivera 2005). Currently there is no consensus on
the optimal therapy for relapsed ALL patients who attain a second disease remission. As
a result the management of relapsed ALL patients remains a major challenge for pediatric
oncologists.
In an attempt to discover potential markers to identify patients with ALL who
may be at risk of leukemia relapse, a small-scale retrospective study was conducted on
125 patients with standard-risk acute lymphoblastic leukemia who had been treated at
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The Children’s Hospital in Denver. The rationale for the current study cohort was: 1)
standard-risk ALL is the largest cohort of childhood acute lymphoblastic leukemia; 2) the
cohort comprised a single class of patients who had been uniformly treated in a single
treatment center. This approach made it possible to determine whether interindividual
variations in treatment response can be explained by genetic polymorphisms that
influence drug disposition. In this study cohort, there were 58% males and 42% females.
Among male participants, 56% and 58% of males were in the relapsed and EFS groups,
respectively. Gender did not present any significant difference with regard to the risk of
leukemia relapse (P = 0.91). This finding is in agreement with all previous studies.

6.1.

Phase I Drug Metabolism Enzymes
As described in the previous chapters, cytochrome P450 enzymes play a critical

role in the metabolism of several chemotheraputic agents including cyclosphamide,
doxorubicin and glucocorticoids that are commonly used in both intial induction and
maintenance phase of pediatric ALL therapy. It had been suggested that polymorphisms
in the genes that encode these enzymes might contribute to treatment outcome (Relling
2001, Fleury 2004, Aplenc 2003). In the current study, no statistically significant
association was found between an altered risk of leukemia relapse and polymorphsims in
the CYP1A1 (rs1048943), CYP2B6 (rs3211371), CYP3A4 (rs2740574) or CYP3A5
(rs10264272) genes. The one exception was CYP3A5 (rs776746) which was found to be
associated with an increased risk of relapse in patients with the variant genotype (HR =
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5.70, 95% CI = 0.743 – 43.694, P = 0.09). No patients in the EFS group carried the
variant alleles and only one patient in the relapsed group carried heterzygous allele (P =
0.01). Although this allele frequency difference reached statistical significance, it should
be noted that due to the small population of the relapsed group, this result was based on a
single patient who carried the variant genotype. This finding should not be considered
significant. The Kaplan-Meier survival curves shown in Figures 6.1, 6.2, 6.3, 6.4, and
6.5 illustrate these findings.
Aplenc et al. (2003) reported a study on the CCG-1891 standard-risk ALL trial.
Genotypes were determined for 533 of the 1203 patients enrolled in the trial which
included 121 relapsed patients and 412 control patients who were in remission status. In
that study, no association was found between a risk of leukemia relapse and CYP3A4
(rs2740574) and CYP3A5 variants (rs10264272; rs776746) (OR = 1.19, 1.02, and 0.79
respectively). Similarly, no association between gene-gene interactions and relapse risk
was observed either. The study did, however, detect an association between the
CYP3A4/CYP3A5 variants and decreased toxicity. Fleury et al. (2004) subsequently
reported their finding of no association between CYP3A4 variants and ALL treatment
outcome. The study included 222 patients treated on DFCI protocols 87-01, 91-01, or 9501. There were 33 patients who experienced a relapse and 20 who died. Rocha et al.
(2005) reported a St. Jude study with 247 patients with newly diagnosed ALL who were
treated on the using the Total XIIB protocol. There were 47 adverse events including
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relapse, second malignancies, and deaths in CR. No association was observed, however,
between the risk of relapse and CYP3A4 or CYP3A5 genotypes.
The only positive association between CYP variants and risk of leukemia relapse
was found in a Canadian study. Krajinovic et al. (2002a) conducted a study on 320
pediatric ALL patients treated on DFCI protocols 87-01, 91-01, and 95-01. Sixty-four
patients experienced an event which was defined as disease relapse or a fatal outcome
during or after the first CR. They studied risk of relapse and functional polymorphisms in
genes encoding drug metabolizing enzymes including CYP1A1, CYP2D6, CYP2E1. In
this study, the presence of CYP1A1*2A variants was associated with an increased risk of
relapse (HR = 2.3, 95% CI = 1.1-4.9, P = 0.03). Although they noted that CYP1A1 is not
thought to metabolize any of the chemotherapeutic agents used with the DFCI protocols.
In the current study, CYP2B6 variant allele frequency difference was not
observed between the EFS group and relapsed group (19.5% vs. 18.7% respectively, P =
0.923). There was no effect of CYP2B6 variant on the risk of relapse (HR = 0.80, 95% CI
= 0.23-2.80, P = 0.721). To the best of the current author’s knowledge, there are no
reports regarding CYP2B6 polymorphisms and the risk of leukemia relapse in pediatric
ALL. Cyclophosphamide is given as a prodrug which must undergo activiation during
phase I metabolism by cytochrome P450 enzymes including CYP2B6. The active
metabolite, 4-hydroxy-cyclophosphamide, is responsible for cyclophosphamide’s
alkylating effect (Huitema 2000). CYP2B6 should play a major role in this process
because it has a higher affinity for the substrate than CYP2C9, CYP2C19, CYP3A4, or
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CYP3A5 (Patterson 2002, Wall 2003). Ekhart et al. (2008) conducted a study to evaluate
effects of genetic polymorphisms on the pharmacokinetics of cyclophosphamide in 124
cancer patients treated with a high-dose chemotherapy (4-6 g/m2 of cyclophosphamide).
They found no effect of polymorhphisms in the CYP2B6, CYP2C9, CYP3A4, CYP3A5
GSTA1, GATP1, ALDH1A1, and ALDH3A1 genes on the clearance of cyclophosphamide.
These results may indicate the CYP2B6 variants alone are not crucial factors affecting
the pharpharcokinetics of cyclophosphamide. The findings from the current study
certainly agree with Ekhart’s results.
From the CCG-1891 study, Aplenc et al. (2003) observed that CYP3A4 and
CYP3A5 variants were associated with decreased chemotherapeutic toxicity; specifically
peripheral neurotoxicity. All patients were followed for more than 5 years after
completion of therapy. Toxicity data were collected prospectively during the study. As
there were no toxicity data available from the study cohort employed for the current
research, an association analysis could not be performed.
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Summary: It should be noted that all of the above studies have limitations. These studies
included patients from different treatment protocols who, therefore, received different
types of corticosteroids and dosages (even within DFCI protocols). The small samples
sizes (drawn from patient subsets) diminish the statistical power of the analyses that
were performed. Another issue of concern is how representative the genotypes are since
the DNA was extracted from the leukemic blasts rather than from from patient germline
cells. Caution, therefore, should be taken with respect to drawing broad conclusions
pertaining to phase I drug metabolizing enzyme polymorphisms and treatment responses.
The findings from the current study were in agreement with some previous studies but
not others.

6.2. Phase II drug metabolism enzymes
Phase II drug metabolism involves conjugation of molecules to the products of
phase I reactions to facilitate excretion. Glutathione S-transferases (GSTs) function as
dimers by catalyzing the conjugation of mutagenic electrophilic substrates to glutathione.
Some of the most studied GST polymorphisms including GSTP1*B (rs1695) which alters
substrate affinity, GSTP1*C (rs1138272) which alters the catalytic activity and the
GSTM1 and GSTT1 null genotypes - both of which lead to loss of enzyme activity. GST
enzymes metabolize numerous chemotherapeutic agents such as glucocorticosteroids,
vincristine, methotrexate, and cyclophosphamide. Consequently, polymorphisms in any
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of these GST genes have significant potential to influence the treatment response of
patients with pediatric ALL.
In the current study, GSTP1*C was observed in 94% of relapsed patients and 83%
of EFS patients. This finding represents an apparent 3-fold difference in risk of leukemia
relapse although it did not reach statistical significance (HR = 0.341, 95% CI = 0.05-2.58,
P = 0.298). GSTP1*B did not show a significant difference between the relapse group
and the EFS group as can be seen in Figures 6.7 and 6.8. A protective effect was
observed, however, with the GSTM1 and GSTT1 null alleles (HR = 0.394 and 0.662,
respectively). Seventy-five percent of relapsed patients had the GSTM1 gene present vs.
56% of EFS group. Thus, these genotypes appeared to be associated with a more than 2fold decreased in the risk of relapse. This association, however, did not reach statistical
significance in the current study as can be seen in Figures 6.9 and 6.10. The GSTM1 and
GSTT1 genotypes were also grouped for the purposes of statistical analysis. In the current
study, the patients having both the GSTM1 and GSTT1 non-null genotype had a 2.7-fold
(HR = 2.7, 95% CI=0.9-7.9, P = 0.063) increased risk of relapse relative to those patients
who carried either a GSTM1 null or GSTT1 null genotype. This finding (Figure 6.6) was
the strongest association in the current study. These findings are supported by the
BFM case-control study with 128 patients treated on ALL-BFM trails 86 and 90
(Stanulla, 2000). In that study, the GSTM1 and GSTT1 null genotypes conferred a 2-fold
and 2.8-fold difference in risk of relapse when compared to the presence of GSTM1 or
GSTT1. A significant reduction in CNS relapse risk in patients who carried the GSTP1*B
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genotype was also found although the effect was only observed in patients with
intermediate or high risk of treatment failure. Furthermore, analyses that examined the
risk of relapse with the normal genotype (non protective) vs. any one, two or three
protective genotypes was performed. These analyses demonstrated an effect with the
addition of each protective genotype (OR = 0.53, 95% CI = 0.24-1.19, P = 0.123 and OR
= 0.29, 95% CI = 0.06-1.37, P = 0.118 respectively) compared to the reference group
with no low-risk genotype (GSTM1 null, GSTT1 null, and GSTP1 Val 105 /Val 105 ).
Rocha (2005) reported on a St. Jude Total Therapy XIIIB trial with 246 patients.
After correcting for other risk factors such as WBC, certain translocations, day 19
marrow, treatment arms and risk group, it was demonstrated that the GSTM1 non-null
genotype was associated with a significantly increased risk of hematologic relapse (HR =
18.1, 95% CI=3.9-84.3, P = 0.002). Other studies, however, did not find a statistically
significant association. Chen et al. (1997) reported on a St. Jude study of Total Therapy
XI, XII, and XIIIA trials with 161 of 525 patients enrolled and found no significant
inpact impact of GSTM1 and GSTT1 null genotypes on risk of leukemia relapse.
Interestingly, in a subset analysis an apparent association was noted between the GSTM1
null genotype and a decreased risk of CNS relapse although this did not reach statistical
significance (HR = 0.90, 95% CI = 0.83 – 0.97, P = 0.054).
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Thus far, the largest studies indicated no association between GST genotypes and
risk of disease relapse. Davies (2002) studied 710 patients including 107 who had
experienced bone marrow relapse and 25 who had experienced CNS relapse. The patients
were from the CCG protocols 1881, 1882, 1883 and 1901 representing a total of 4087
enrolled patients. In the analysis, an association between GSTM1 and GSTT1 null
genotype and the risk of disease relapse was not observed. A Kaplan-Meier survival
curve also demonstrated the lack of a difference in the overall survival with either
genotype. One caveat, that should be noted, however, is that despite the large sample
size, the genotyped patients had a lower relapse rate than the aggregate of all enrolled
patients. Krajinovic (2002a), based on a similiar study to that described in the prior
section on patients treated with DFCI protocols, found no association between the
GSTM1, GSTT1 or GSTP1 genotypes and the risk of leukemia relapse. Again, however, it
is important to emphasize that the patient population consisted of different risk groups.
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Summary: The current study demonstrated an association between GSTM1 deletion and
a decreased risk of disease relapse (HR = 0.39, 95% CI = 0.13-1.22, P = 0.107) in the
pediatric standard-risk ALL patients treated at The Children’s Hospital in Denver, CO.
When the GSTM1 and GSTT1 genotypes were combined in the analysis, there was an
even stronger apparent association with the risk of relapse (HR = 2.73, 95% CI = 0.907.90, P = 0.063). Although neither of these reached a statistical significance (P = 0.05)
but the clinical effect was evident with 75% of patients in the relapse group
having the GSTM1 non-null genotype vs. 56% of patients in the EFS group. The KaplanMeier survival analysis shown in Figure 6.6 also illustrates these effects. Sixty-nine
percent of relapsed patients have both GSTM1 and GSTT1 non-null genotypes vs. 46% in
the EFS group. With the excellent EFS rate in the standard-risk ALL, the significance of
this finding should not be underestimated. Of course, the aforementioned studies all have
some limitations. Most were drawn from different risk groups of patients and as a result
the treatment regimens differed greatly. This illustrates the importance of larger
prospective clinical trials with well defined inclusion criteria.

6.3.

Drug Target Enzymes
Methotrexate (MTX) is a common therapeutic agent for both malignant and

nonmalignant diseases. It plays a central role in childhood ALL across all treatment
protocols. MTX interferes with the natural folate cycle by DHFR, TYMS, and MTHFR
and thereby leads to a reduced folate pool, inhibition of nucleic acid synthesis, and
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eventually cell death. Polyglutamated MTX also directly inhibits the enzymes
synthesizing thymidylate and purine. Polymorphisms in the genes encoding those
enzymes, therfore have the potential to influence the treatment outcome in ALL patients.
The MTHFR gene has multiple polymorphic sites with two common non-synonymous
variants, 677C>T and 1298A>C which are associated with reduced enzyme activity. The
MTHFR 677 CT heterozygous genotype is associated with a 40% decrease in enzymatic
activity while the TT homozygous genotype is associated with a 70% reduction in
enzymatic activity (Schwahn 2001). The TYMS gene has a 28-bp insertion in the
promoter region. Triple repeats (3R) of this insertion have been associated with a higher
level of TYMS expression. Since TYMS is another important target for MTX genetic
polymorphisms in the TYMS, may influence the outcome of ALL treatment.
In the current research, a slightly higher percentage of MTHFR 677 variant
genotypes were observed in the study cohort, i.e., 42% CT heterozygous genotype vs.
20% homozygous TT genotype. It is unclear why the study population employed for the
current research had higher than anticipated frequencies of variant alleles. However the
genotype frequencies were found to be in Hardy-Weinberg equilibrium. Some
researchers have expressed concerns that preferential allele amplification might result in
an analytical genotyping error (Miller 2002). Genotyping results from the current study
were independently confirmed by two individuals. Furthermore, the genotyping assays
were validated throught the use of mutiple assay proficiency panels from the College of
American Pathologists (CAP) and clinical samples (Appendix. 2). The results from the
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current study seem to suggest a protective effect in patients with the MTHFR 677 TT
genotype for the risk of disease relapse. This apparent effect, however, did not reach the
statistical significance (P = 0.221). As illustrated in Figure 6.11, the Kaplan-Meier
survival curve clearly shows that there is no difference between risk of relapse with a
MTHFR 677 TT genotype compared to either the CT or CC genotypes. Several reports
have, however, demonstrated a protective effect of MTHFR 667 and MTHFR 1298
polymorphisms on leukemia susceptibility risk (Franco 2001). Taub (2002) reported that
leukemic cells with the MTHFR 677 variant alleles had an increased sensitivity (in vitro)
to MTX. This finding suggested that patients who carried the variant genotypes should
have a decreased risk of leukemia relapse. Most of clinical trials have appeared to
indicate either an increased risk of relapse or decreased EFS.
With regard to TYMS polymorphisms in the current study, a higher frequency of
the 3R/3R genotype was found in the EFS group. Thirty-percent of patients in the EFS
group were observed to have a 3R/3R genotype while only 13% of those in the relapsed
group showed this genotype. The 3R/3R genotype, therfore appeared to be associated
with a decreased risk of relapse in the current study cohort (HR = 0.40, 95% CI = 0.091.77, P = 0.227), although this did not reach statistical significance. Most of recent
studies have indicated that patients with a 3R/3R genotype were at higher risk of disease
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relapse. Krajinovic et al. (2002b) evaluated 205 patients treated with DFCI protocols as
described in the MTHFR section. Patients in that study with the 3R/3R genotype were
found to have a higher risk of adverse event (OR = 4.8, 95% CI=1.1-20.1, P = 0.04). This
effect remained when the control group contained only patients with a CR > 5 years. The
survival analysis demonstrated similar statistical significance.
Lauten (2003) reported their findings with patients treated on BFM protocols 86
or 90. The increased risk of relapse that had been reported by others for the 3R/3R
genotype was not evident in Lauten’s case-control study of 80 pediatric ALL patients
who received the same amount of MTX (4 g/m2). Likewise, the St. Jude Total Therapy
XIIIB study did not observe an impact related to the 3R/3R genotype (Rocha 2005).
Interestingly, the same group of investigators (Relling 2004) reported that patients with
the 2R/2R genotype had a significantly increased risk for a specific adverse event; that
being osteonecrosis of the hip (OR = 7.2, 95% CI=1.1-48.9, P = 0.044).
During the current study, a gene expression profiling and MTX response study of
ALL was published by St. Jude investigaters (Sorich 2008). In that study, genome-wide
expression profiling was conducted to identify genes whose expression appeared to be
linked to in vivo MTX response based on a drop in the WBC on day 3 following highdose MTX admnistration. A total of 293 patients with newly diagnosed ALL, who were
enrolled in the Total Therapy XIII and XV protocols, were included in the study. The
study found 48 genes and 2 cDNA clones that were stronly linked to the in vivo MTX
response. Among those were genes involved in nucleotide metabolism (TYMS and
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CTPS). The study showed that low expression of TYMS was significantly associated
with poor in vivo MTX response. Univariate hazard analysis of the risk of relapse
produced HR of 0.60 (P = 0.008). Interestingly, other known genes involved in the folate
metabolism pathway were not among the top 50 putatively associated genes. This finding
suggested that de novo MTX resistance may be acquired during treatment rather than
predisposed as was previously thought. Unfortunately RNA is not available for a similar
analysis of the patients enrolled in the current study.
Summary: The current study did not find that either MTHFR or TYMS variants were
associated with an increased risk of leukemia relapse (Figure 6.12 and 6.13). On the
contrary, the results suggested that they might have a slight protective effect against the
risk of relapse. These discordant findings may be due to difference in study design,
population size, and/or therapeutic regime (e.g., schedule of treatment, dosage, and
coadministration of other therapeutic drugs). As a consequence of the heterogeneity of
the available studies, comparisons among these studies are very difficult if not
impossible. None of the studies mentioned the quality of the genomic DNA that was used
in the analysis. As mentioned above, this illustrated again the importance of larger,
prospective trials that consistently and carefully assessed study end points. Moreover,
these trials need to collect comprehensive data on variables such as chemotherapy
dosage, treatment compliance data, malignacy phenotype and genotype, etc..
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6.4.

Conclusion and Future Perspectives
The current study provides important new information on the potential role of

drug metabolizing enzyme polymorphisms and the risk of leukemia relapse in pediatric
patients treated with standard-risk acute lymphoblastic leukemia at The Children’s
Hospital in Denver, CO. This study found an association between the GSTM1 null
genotype and a decreased risk of relapse (HR = 0.394, 95% CI=0.124-1.224, P = 0.144).
An even greater effect was observed in terms of an increased risk of disease relapse for
the combination of both GSTM1 and GSTT1 genes being non-null versus the presence of
either the GSTM1 or GSTT1 null genotype (HR = 2.73, 95% CI=0.0-7.9, P = 0.063). Both
conditions approached (but did not reach) statistical significance, however, the clinical
impact could be more important as this appears to be the first study to demonstrate the
effect of GSTM1 and GSTT1 null genotype with risk of leukemia relapse with standardrisk pediatric ALL. It is important to recognize that these findings should only be applied
in the conext of this specific treatment protocol but not other protocols.
None of the other genetic polymorphisms in the current study showed a
significant association with the risk of disease relapse after successful induction therapy.
Moreover, the current study did not show a significant association between either the
MTHFR 677 variants or the TYMS 3R/3R genotype and risk of relapse as described in
previously reported CCG studies. This discrepancy might be explained by: 1) the limited
scale of the current study which may not have a sufficiently large patient population,
(especially in the relapsed group), to detect a modest host genetic effect on the risk of
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relapse; 2) the presence of treatment heterogeneity may obscure modest genetic effects,
and/or 3) the complexity of the treatment protocol which not only involves multiple
interacting chemotherapeutic drugs but also over-the-counter medications and herbal
supplements. Patient compliance is also an important factor. Unfortunately, the ability to
capture and quantify these variables in most association studies is extremely limited.
Clearly, the relatively small scale of the current study necessitates that the
findings should be interpreted with caution. The findings from the current study may be
protocol specific and a genetic polymorphism that is a significant indicator of relapse in
the current study may emerge as irrelevant in another. The improvements that have been
achieved in pediatric ALL outcome are largely attributed to refinements in multi-drug
chemotherapy protocols. They are administered at maximum tolerant doses for the
pediatric population. It is therefore unlikely that we can further improve the outcome of
ALL patients by dose-escalation of existing therapies due to the enormous toxicity that
these drugs have on the active developmental pathways of pediatric patients. In the last 5
years, pharmacogenomic studies have shifted to high-resolution genome-wide association
studies in an effort to better understand the fundamental molecular biology of acute ALL
and to identify potential markers related to treatment outcome as well as to identify novel
therapeutic targets. Despite these advances, the pharmacogenetic of ALL remains as one
of the most promising areas for continued investigation. The findings from the current
study underscore the need for and the value of prospective, large multi-institutional
studies as a major thrust in the ongoing effort to improve the survival of ALL patients.
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ABBREVIATIONS
ALL
AML
AZA
BFM `
BCB
CCG
CI
CP
CR
Ct
CYP
DFCI
DHFR
EFS
FAB
6-FAM™
GST
HSC
HPRT
HR
MGB
6MP
MTHFR
MTX
NFQ
OR
POG
RBC
SJCRH
TPMT
TYMS
WBC
WHO

acute lymphoblastic leukemia
acute myeloid leukemia
azathioprine
Berlin-Frankfurt-Munster Study Group
comple blood count
children’s cancer group
confidence interval
cyclophosphamide
complete remission
cycle threshold
cytochrome P450
Dana Farber Cancer Institute
dihydrofolate reductase
event-free survival
French-American-British
6-carboxyfluorescein
glutathione s-transferase
hematopoietic stem cell
hypoxanthine phosphoribosyl transferase
hazard ratio
minor groove binding
6-mercaptopurine
5, 10-methylenetetradyfrofolate reductase
methotrexate
nonfluorescent quencher
odds ratio
pediatric oncology group
red blood cell
St Jude Children’s Research Hospital
thiopurine s-methyltransferase
thymidylate synthetase
white blood cell count
world health organization
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Appendices
Appendix 1. DNA Isolation from Blood or Bone Marrow (BM) – Manual Extraction
I.

PRINCIPLE
Red blood cells (RBCs) are first removed by preferential lysis. WBCs are then lysed to
release lipids, nucleic acids, and proteins. The proteins and lipids are removed by highsalt precipitation while DNA is left in solution. DNA is finally precipitated from the solution
with isopropanol, washed with 70% ethanol and allowed to dry before re-hydrating in a
Tris-EDTA buffer.

II.

SPECIMEN REQUIREMENTS
A.
Acceptable specimens:
1. Blood or bone marrow (BM) aspirate collected in EDTA anti-coagulant
(preferred). Store at 2-8°C upon receipt. For best results, samples should be
left at room temperature for no more than 24 hours prior to processing.
2. Blood or BM collected in ACD (yellow top) or citrate (blue top) are also
acceptable
3. Slides from EDTA- preserved blood or BM, dried, room temp.
B.
Unacceptable specimens:
1. Heparin is a known inhibitor of the PCR; therefore, specimens collected in
heparin are generally not acceptable for PCR-based assays.
2. Clotted specimens will be noted but may be accepted at the discretion of the
technologist.
a.
If a BM sample (irreplaceable) is clotted and WBCs cannot be obtained
from the sample, it may be processed according to the DNA Isolation
from Fresh or Frozen Tissue Protocol.
b.
If a blood sample is clotted and WBCs cannot be obtained from the
sample, another sample must be obtained.

III.

REAGENTS/EQUIPMENT/SUPPLIES
A.

Reagents
1. RBC Lysis Solution, 1000 mL, Cat# 158904, QIAGEN. Store at room
temperature.
2. Cell Lysis Solution, 1000 mL, Cat# 158908, QIAGEN. Store at room
temperature.
3. Protein Precipitation Solution, 350 mL, Cat. # 158912, QIAGEN Store at
room temperature.
4. 2-propanol (isopropanol), molecular biology grade, 500 mL, Cat# I9516500ML, SIGMA. Store at room temperature.
5. Glycogen (20 mg/ml), 100 µL, Cat# 10814-010, INVITROGEN. Store at 20°C.
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6. 70% Ethanol (v/v), prepared in molecular-grade water from 100% ACS/USP
grade ethyl alcohol obtained from TCH pharmacy. Store at room
temperature.
7. DNA Hydration Solution, 100 mL, Cat# 1045698, QIAGEN. Store at room
temperature.
B.

C.

Equipment
1. Centrifuges
a.
Eppendorf 5415R or equivalent benchtop microcentrifuge
b.
Beckman CPKR or equivalent floor-model centrifuge (for large-scale
preps)
2. Pipettors – Use only those designated for Specimen Processing, labeled as
SP##. Use only aerosol-resistant tips (ARTs) for specimen processing.
3. NanoDrop ND-1000 spectrophotometer

Supplies
1. 1.7 mL clear snapcap microtubes, Cat# 22-281, Genesee Scientific
2. 15 mL BD Falcon conical polypropylene centrifuge tube, Cat# C3977-4,
Cardinal Health

IV.

SPECIAL SAFETY PRECAUTIONS
The reagents used in this procedure may cause eye and skin irritation. Exposure may
cause discomfort if swallowed or inhaled. Read the MSDS and follow the handling
instructions. Wear appropriate personal protective equipment. Place all hazardous waste
in the appropriate container.
Stock volumes of alcohols used in this procedure are kept in the flammable liquid storage
cabinet in the reagent prep room. Smaller volumes sufficient for daily use (less than 500
mL) may be aliquoted and stored in the specimen processing room on the benchtop.
Protein Precipitation Solution is known to produce a toxic gas when mixed with bleach.
Empty reagent bottles should not be re-used for hazardous waste. In the event of a
spill, blot up excess with paper towels, then use water to thoroughly clean the area.
Spray-bottle bleach may then be used as necessary for decontamination.

V.

QUALITY CONTROL – Individual reagents are QC’ed and results are documented.

VI.

PROCEDURE -

NOTE: All work must be performed in the biological safety cabinet (hood) with the blower
ON until the final DNA product is ready for hydration, at which point it may safely be
manipulated on an open bench.
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A.

RBC lysis
1.

2.

3.

To a clear 1.7 mL microtube labeled with MDL number, add 900 µL of
RBC Lysis Solution. Add 300 µL of well-mixed patient specimen. Cap
and invert several times to mix. Incubate a minimum of 5 minutes. Spin
tubes for 20 seconds at 8000 rpm in the benchtop microfuge.
Observe the size of the WBC pellet; it should be approximately equal to
the “ideal” pellet size illustrated in Fig. 1 below. If larger than the
illustration, vortex briefly to re-suspend the cells, then divide into 2 or
more tubes and re-spin.
Pipet off the supernatant into the blood/BM waste bottle, leaving behind
10-20 µL of residual fluid. (For Recap and vortex vigorously to resuspend
the WBCs.

Figure 1. "Ideal" WBC pellet size

B.

Cell lysis
1.
Add 600 µL of Cell Lysis Solution and pipet up and down to mix
a.
Blood or BM is processed in a 1.7 mL microtube at a 1:3 ratio with
RBC Lysis Solution (300 µL sample and 900 µL RBC Lysis Solution).
Scale up by using multiple microtubes, or scale down by using less
reagent according to the specimen volume available. For most
procedures two microtubes are preferred.
1. Add 300 µL whole blood (or BM) to a 1.7 mL clear microtube
labeled with the MDL number and containing 900 µL RBC Lysis
Solution. Process 2 microtubes per sample if possible. Invert 10
times. Incubate 5 minutes at room temperature.
2. For slides begin at step IX.A.1.f.
b.
Centrifuge microtubes for 20 seconds at 8,000 rpm in the benchtop
microfuge.
1. Observe the WBC pellet, if the pellet is obscured by RBCs still,
then remove as much of the RBC lysis supernatant as possible
with a pipette and add another 900 µL RBC Lysis Solution.
Vortex briefly and incubate 5 minutes at room temperature and
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c.
d.

e.

re-centrifuge as above. (Some nucleated RBCs may be present,
particularly if the sample is a BM, and these cells may not lyse.)
2. If the WBC pellet is clearly visible remove as much supernatant
as possible with a pipette leaving behind the WBC pellet and
about 10µL of the residual liquid. BM NOTE: Be sure to draw off
all fat floating on the surface of the supernatant, otherwise it will
contaminate the DNA in subsequent steps.
3. Note the size of the WBC pellet to determine whether the pellet
should be divided into more tubes due to its large size or if a
smaller volume of cell lysis solution should be used in the
subsequent steps due to its small size. See Illustration I for an
example of “good” WBC pellet size.
4. Additionally, if more sample is available and the WBC pellet is
small, process more blood or BM to attain enough WBCs to get
plenty of DNA for the tests ordered.
To facilitate cell lysis, vortex the microtube vigorously to resuspend the
white cells in the residual liquid.
Add 300 µL (small WBC pellet) or 600 µL (“good” WBC pellet size) of
Cell Lysis Solution to the resuspended cells and pipette up and down
5-10 times to lyse the WBCs. Samples are stable in Cell Lysis Solution
for at least 18 months at room temperature.
For slides, begin by washing each with ~100 µL of Cell Lysis Solution
and use the side of a pipettor tip to scrape the material from the slide
into a 1.7 mL clear microtube labeled with the MDL number.

2. Protein Precipitation
a.
Add 100 µL (to the 300 µL volume) or 200 µL (to the 600 µL volume) of
Protein Precipitation Solution to the cell lysate. (33 µL protein
precipitation solution per 100 µL cell lysate).
b.
Vortex vigorously at high speed for at least 20 seconds to mix the
Protein Precipitation Solution uniformly with the cell lysate. Watch for
precipitation of the proteins into many red particles in the solution. The
solution is well mixed when this appears. If this does not occur after 20
seconds, vortex vigorously until precipitation is noted or until another
30 seconds have elapsed, whichever comes first. Not all samples will
appear precipitated; however the proteins will spin-down upon
centrifugation.
c.
Centrifuge at 13,000-16,000 rpm for 3 minutes. The precipitated
proteins will form a tight, dark brown pellet. If the pellet is not tight at
the bottom of the microtube, centrifuge for an additional 10 minutes at
13,000-16,000 rpm.
3. DNA Precipitation
a. Carefully pour the supernatant containing the DNA into a 1.7 mL clear
microtube containing 300 µL 100% Isopropanol (for samples using only
300 µL cell lysis solution) or 600 µL 100% Isopropanol (for samples
using 600 µL cell lysis solution). (1 to 1 ratio isopropanol and original cell
lysis volume).
b. Mix the sample by inverting at least 15 times. DNA may or may not be
observed.
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c.

d.

e.
f.
g.

h.

1. If DNA is observed continue inverting until the mass of DNA is a
tighter clump rather than a loose, foamy appearing substance.
2. If DNA is not observed add 1 µL of Glycogen and continue
inverting another 15 times.
Centrifuge at 13,000-16,000 rpm for 3 minutes if DNA was observed
while inverting. Centrifuge for 10 minutes if DNA was not observed
while inverting and Glycogen was added. The DNA pellet will be visible
as a small white pellet.
Pour off the supernatant, discarding it in the designated hazardous
waste container (Alcohol), and drain the microtube briefly on clean
absorbent paper, making sure the DNA pellet remains in the
microtube.
Add 300 µL 70% Ethanol and gently swirl the liquid over the DNA pellet
by partial inversion 10 times to wash the DNA pellet.
Centrifuge at 13,000-16,000 rpm for 3 minutes.
Remove the supernatant with a pipette tip and discard in the
designated hazardous waste container (Alcohol), leaving behind only
the DNA.
Allow DNA to dry at room temperature for 10 minutes or until there is
no moisture in the tube. The white DNA pellet will turn translucent.

4. DNA Hydration
a.
Add DNA hydration solution according to the size of the DNA pellet.
1. If DNA was visible when precipitating (at step IX.A.3.b) add a
minimum of 25 µL DNA hydration solution.
2. If Glycogen was used to pellet the DNA, hydrate with a maximum
of 12 µL DNA hydration solution.
3. Do not over-hydrate. A sample is easy to dilute but difficult to reconcentrate.
4. Generally, 50 µL DNA hydration solution will achieve the desired
0.500 µg/µL concentration if the original WBC pellet appeared as
shown in Illustration I.
b.
If the specimen is required the same day, vortex 5 seconds at medium
speed to mix and briefly centrifuge to collect sample at the bottom of
the microtube before incubating at 56°C.
c.
If the specimen is to be tested on subsequent days, allow the hydrated
sample to sit at room temperature overnight.
d.
Combine all microtubes that originated from the same sample and
label this tube with the MDL number on a white LabPal label (i.e.
093455 for 09-MD-3455).
B.

MEASUREMENT OF DNA CONCENTRATION
1. Determine DNA concentration and purity using the NanoDrop ND1000.
Pipette 2.0 µL of hydrated DNA onto the NanoDrop platform (as little as 1 µL
may be used). Good quality DNA should have a 260/280 ratio between 1.7
and 2.0.
2. Optimal DNA concentration is between 0.1 and 0.5 µg/µl. If the concentration
is higher than this, add additional DNA hydration solution to reach this target
concentration.
3. Record the DNA concentration (µg/µl) and purity on the side of the sample
microtube.
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4. Record DNA concentration and purity on the extraction sheet to be entered in
the MDL database.
5. Refer to the NanoDrop ND1000 Spectrophotometer Procedure for additional
information.
C.

DNA STORAGE
1. Store DNA at room temperature overnight to allow for complete hydration.
2. DNA long term storage is in the -70°C freezer in a designated storage box to
be held for testing, potential further testing and/or to be used in quality
control testing.
3. The adequacy of storage at –70°C is monitored by analysis of current testing
performance using controls stored under identical conditions.
4. Specimens are maintained in a limited access, secured area at all times. The
Molecular Diagnostic Laboratory specimens are stored in a coded manner.
Laboratory personnel are present when the lab is open. The laboratory has
no public access.

VII.

Reference Range

VIII.

Method Limitations

IX.

REFERENCES
A.
Gentra Puregene Handbook, 4/2010, Qiagen

X.

Related Documents
A.
NanoDrop ND1000 Spectrophotometer Procedure
Attachments
A.
Document Historical Record
B.
DNA Isolation Blood BM Summary Flowchart

XI.

Illustration I
Ideal WBC pellet size. If much larger than this (for example 2x as large), please aliquot into
additional clear microtubes. If much smaller than this (for example ½ as large), please use the
smaller amount (300 µL) of Cell Lysis Solution and process more of the sample to attain more
WBCs.
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Appendix 2. Clinical validation: MTHFR C677T and MTHFR A1298G

ARUP
Laboratories Results

TCH MDx Lab Results
MTHFR 677
Wild type

MTHFR 677
Variants

MTHFR 677
Wild type

7

0

MTHFR 677
Variants

0

26

CAP proficiency
Survey

TCH MDx Lab Results
MTHFR 677
Wild type

MTHFR 677
Variants

MTHFR 677
Wild type

2

0

MTHFR 677
Variants

0

6

ARUP
Laboratories Results

TCH MDx Lab Results
MTHFR 1298
Wild type

MTHFR 1298
Variants

MTHFR 1298
Wild type

4

0

MTHFR 1298
Variants

0

4
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Appendix 4. Data Coding: i
if CYP1A1=2 then CYP1A1g=2;
if CYP1A1=1 then CYP1A1g=1;***reference group;
if
if
if
if
if
if

CYP2B6=3
CYP2B6=2
CYP2B6=1
CYP3A4=3
CYP3A4=2
CYP3A4=1

then
then
then
then
then
then

CYP2B6g=2;
CYP2B6g=2;
CYP2B6g=1;***reference group;
CYP3A4g=2;
CYP3A4g=2;
CYP3A4g=1;***reference group;

if
if
if
if
if
if
if
if

CYP3A5_1=2 then CYP3A5_1g=2;
CYP3A5_1=1 then CYP3A5_1g=1;***reference group;
CYP3A5_2=1 then CYP3A5_2g=2;
CYP3A5_2=2 then CYP3A5_2g=2;
CYP3A5_2=3 then CYP3A5_2g=1;***reference group;
GSTP1_1=3 then GSTP1_1g=2;
GSTP1_1=2 then GSTP1_1g=2;
GSTP1_1=1 then GSTP1_1g=1;***reference group;

if GSTP1_2=3 then GSTP1_2g=2;
if GSTP1_2=2 then GSTP1_2g=2;
if GSTP1_2=1 then GSTP1_2g=1;***reference group;
TSg=TS;
if MTHFR667=3 then MTHFR667g=2;
if MTHFR667=2 then MTHFR667g=2;
if MTHFR667=1 then MTHFR667g=1; ;***reference group;

if MTHFR1298=3 then MTHFR1298g=2;
if MTHFR1298=2 then MTHFR1298g=2;
if MTHFR1298=1 then MTHFR1298g=1;***reference group;

if GSTM1=2 then GSTM1g=2;
if GSTM1=1 then GSTM1g=1;***reference group;
if GSTT1=2 then GSTT1g=2;
if GSTT1=1 then GSTT1g=1;***reference group;

if CYP3A4=1 and CYP3A5_1=1 and GSTM1=1 and GSTT1=1 then DrugExpo=3;
if (CYP3A4=1 or CYP3A5_1=1) and (GSTM1=2 or GSTT1=2 ) then DrugExpo=3;
if CYP3A4=2 and CYP3A5_1=1 and GSTM1=. and GSTT1=. then
DrugExpo=3;***All others;
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if (CYP3A4=1 and CYP3A5_1=1) and (GSTM1=2 or GSTT1=2 ) then
DrugExpo=2;***High drug exposure;
if (CYP3A4 >1 or CYP3A5_1=2) and (GSTM1=1 and GSTT1=1 ) then
DrugExpo=1;***low drug exposure;
*** 1 vs 2;
if DrugExpo =1 then DrugExpoA=1;***low drug exposure;
if DrugExpo = 2 then DrugExpoA=0;***High drug exposure;
*** 1+3 vs 2;
if DrugExpo in (1, 3) then DrugExpoB=1;***low drug exposure + all
others;
if DrugExpo = 2 then DrugExpoB=0;***High drug exposure;

*** Drug shorter stay vs longer stay;
if GSTM1=1 and GSTT1=1 then DrugExpo2=1;***Drug stay shorter;
if GSTM1=2 or GSTT1=2 then DrugExpo2=0;***Drug stay longer;

i
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